

EPA ADMINISTRATIVE OFFICE

15 Avenue de la Liberté 67000 Strasbourg, France Tel: + 33 3 88 23 99 30

EPA BRUSSELS OFFICE

University Foundation Rue d'Egmont 11 1000 Brussels, Belgium Tel: +32 2 511 02 30

CONGRESS SECRETARIAT



Kenes International Organizers of Congresses S.A. Rue François-Versonnex 7 1207 Geneva, Switzerland Tel: +41 22 908 04 88 Fax: +41 22 906 91 40

epa@kenes.com

www.epa-congress.org

CONGRESS PROGRAMME

CONGRESS INFORMATION	
Welcome Message	3
General Information	4
Congress Activities	7
EPA Forum	8
Information for Presenters	10
e-Posters and e-Poster Presentations	11
Mobile Application, Internet and Wifi	12
Congress Accreditation and Certificate of Attendance	13
Early Career Psychiatrists' (ECP) Programme	16
About the European Psychiatric Association	17
EPA Prizes and Awards	18
EPA 2019 Scientific Programme Overview	20
EPA Membership	22
SCIENTIFIC PROGRAMME	
Saturday, 6 April	25
Sunday, 7 April	
Monday, 8 April	71
Tuesday, 9 April	109
INDEX OF AUTHORS	137
COMPANY & EXHIBITION GUIDE	
Acknowledgements	145
Industry Supported Satellite Symposia	148
Exhibition Floor Plan	152
List of Exhibitors	153
Company Profiles	1 /



WELCOME MESSAGE

Dear Colleagues,

The **27**th **European Congress of Psychiatry**, organised by the largest international association of psychiatrists in Europe, is taking place between 6 and 9 April 2019 in Warsaw, the capital and largest city of Poland, a significant cultural, political and economic hub, where the historical old town has been designated a UNESCO World Heritage Site, and the stock exchange ranks first among those of Central and Eastern Europe.

You will be truly fascinated by the history and atmosphere of Warsaw, which combines the influences of Western and Eastern Europe, and where tradition meets modernity.

We will also have a nice opportunity to meet many colleagues from neighbouring countries such as Russia, Belarus, Ukraine and the Baltic countries.

The motto of the congress is "Psychiatry in Transition: Towards New Models, Goals and Challenges".

Psychiatry is facing a generative transition involving the organisation of mental health services, traditional approaches to diagnosis, models of care, and research paradigms. The implementation of community-based mental health systems in many countries, the increasing emphasis on person-centred research and care, the availability of scientific evidence substantiating the bio-psycho-social model, the clinical relevance of the diachronic perspective, and the effectiveness of e-mental health interventions represent meaningful examples of the ongoing transition.

We feel confident that the EPA 2019 congress will help all of us to adopt new models and to meet the challenges of new research findings for the benefit of our patients. A special focus of the congress is going to be the update of evidence-based medicine in psychopharmacology, implementation of community-based mental health systems, e-mental health applications, and prevention programmes.

We know that this congress will continue with the best traditions of the EPA and will represent for all participants an unforgettable personal and professional experience.

We therefore are delighted to welcome you to Warsaw, one of Europe's most dynamic metropolitan cities.



Silvana Galderisi EPA President & SPC Co-Chair



Philip Gorwood

EPA President Elect
& SPC Chair



Agata Szulc Local Organising Committee Co-Chair



Jerzy Samochowiec
Local Organising
Committee
Co-Chair

GENERAL INFORMATION

CONGRESS VENUE

WARSAW EXPO XXI

Prądzyńskiego 12/14, 01-222, Warsaw, Poland | Telephone: +48 22 256 7100 www.expoxxi.pl/en

LANGUAGE

English is the official language of the congress.

REGISTRATION

The Registration Desk is situated in Pavilion 2 at the congress venue and will be open during the following hours:

Saturday, 6 April	8:00 - 20:00
Sunday, 7 April	7:00 - 20:30
Monday, 8 April	7:30 - 18:45
Tuesday, 9 April	7:30 - 15:00

LOCAL INFORMATION

A Local Information desk situated in the Registration Area offering local city information to congress participants will operate during the following hours: Saturday, 6 April – Tuesday, 9 April 9:00 – 17:00

EPA BOOTH OPENING HOURS

The EPA Booth is located in the Exhibition Hall and will be open at the following times:

 Sunday, 7 April
 9:00 - 17:00

 Monday, 8 April
 9:00 - 17:00

 Tuesday, 9 April
 9:00 - 15:00

Note: EPA membership payments can be made at the EPA booth until 16:30 on Sunday, 7 April.

EXHIBITION OPENING HOURS

Sunday, 7 April	9:00 - 17:00
Monday, 8 April	9:00 - 17:00
Tuesday, 9 April	9:00 - 15:00

NAME BADGE

Upon registration, you will receive your name badge. You are kindly requested to wear your badge during all congress sessions and events.



CONGRESS CERTIFICATES

CME/CPD

After the congress, all registered participants will receive an email with a link to the congress survey and the credit claiming procedure. Your CME/CPD certificate will be delivered electronically after completing the education evaluation and credit claiming process. For more information, please see pages 13–15. Printed certificates will not be available at the congress.

EPA COURSES

The course certificate of attendance will be delivered electronically after completing the educational evaluation online. The link to the evaluation form will be sent to each course participant shortly after course completion.

F-POSTERS

E-Poster certificates will be automatically sent after the congress to all poster presenters whose registration payment was received.

ABSTRACTS

All accepted abstracts submitted by the deadline are published in an online supplement of the *European Psychiatry* journal published by Elsevier. Abstract viewing is also available on the congress website and app.

COMPANY AND EXHIBITION GUIDE

In accordance with compliance regulations, Industry supporting the congress has been acknowledged separately from the Scientific Programme. Industry Information appears at the back of the book, under the section entitled "Company and Exhibition Guide."

REFRESHMENTS AND BREAKS

Refreshments and lunch will be provided during the breaks in the Exhibition area, located in Pavilion 1.

MOBILE PHONES

Mobile phones must be switched off or muted during all sessions.

SMOKING POLICY

Smoking is prohibited throughout the congress venue. Please be considerate of the rules of the venue and your fellow participants.

PHOTOGRAPHY AND RECORDING PRIVILEGES

No photographs, video recording or audio recording is permitted in the scientific sessions at this congress unless otherwise authorised by the Scientific Programme Committee or the FPA President

PUBLIC TRANSPORTATION OPTIONS

TRAIN

From Warsaw center to Expo XXI

- In Warsaw Downtown Station (Warszawa Śródmieście) Please go to platform 3 (peron 3)
- Please use the SKM (Fast Urban Railway) lines S2 or S3 to Warszawa Zachodnia station (Warszawa Zach.) in direction of Warsaw Chopin Airport.
- Please use the underpass to leave Platform 3 in direction of Tunelowa St. (ul. Tunelowa) and exit the Warszawa Zachodnia station (Warszawa Zach.)
- Turn right on Tunelowa St. (ul. Tunelowa) and walk until you reach Prądzyńskiego streets (approx. 4 minutes' walk)
- Turn left on Prądzyńskiego streets and walk to Expo XXI (approx. 5 minutes' walk)

Expo XXI to Warsaw center

- Exit Expo XXI and turn left on Prądzyńskiego streets until you reach Tunelowa St. (ul. Tunelowa) (approx. 5 minutes' walk)
- Please turn right on Tunelowa St. (ul. Tunelowa) and walk until you reach the Warszawa Zachodnia station (Warszawa Zach.) (approx. 4 minutes' walk)
- In Warszawa Zachodnia station (Warszawa Zach.) Please go Platform 2 via the underpass.
- Please use the SKM (Fast Urban Railway) lines S2 or S3 to Warsaw Downtown Station (Warszawa Śródmieście)

VETURILO: THE WARSAW PUBLIC BIKE

Veturilo is one of the largest urban bike systems in Europe, offering an alternative means of transport and allowing quick navigation through the city. 5300 Veturilo bicycles are available around the clock in over 370 stations throughout Warsaw city centre.

Please find all relevant information on bike hiring, rental cost, bike stations location in Warsaw here: www.veturilo.waw.pl/en/

FREE PUBLIC TRANSPORT WITH CONGRESS BADGE

The congress badge, accompanied by a photo ID, authorise the holder to travel free of charge on local public transport in the capital city of Warsaw within the 1st ticket zone from 6-9 April 2019.

LIABILITY AND INSURANCE

The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised not to leave their personal belongings unattended in session halls and throughout the congress venue.

GUEST ATTENDANCE POLICY

All event activities (including educational sessions, meal functions, exhibition hall, etc.) are exclusively reserved for registered attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in any of the event areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

EMERGENCY TELEPHONE NUMBERS

Fire department, Police and Ambulance services are available via telephone number 112.

CONGRESS ACTIVITIES

SATURDAY, 6 APRIL

EPA FORUM

Implementing Comprehensive, Evidence-Based and Rights-Centred Strategies for Mental Health Care across Europe

9:00 - 13:30 | Hall B

OPENING CEREMONY 18:30 – 20:00 | Hall A

Followed by a
WELCOME RECEPTION
20:00 | Hall A

EARLY CAREER PSYCHIATRISTS' NETWORKING EVENING

(ticket required) 21:00 | Pavilion 3

The EPA wishes to welcome delegates to the congress and provide them with a valuable opportunity to meet new colleagues.

NEW

New this year during the Networking Evening: the ECP Quiz, a game show event full of teamwork, fun & prizes! Tickets at €15 per person are available at the Registration Desk or at the door for all registered participants.

SUNDAY, 7 APRIL

EPA ORDINARY GENERAL ASSEMBLY

18:45 Hall B

This event is reserved for EPA members.

Please collect your invitation for this event from the EPA booth in the Exhibition Area.

Note: EPA membership payments can be made at the EPA booth until 16:30 on Sunday, 7 April.

EPA FORUM

The 5th **EPA Forum** "Implementing Comprehensive, Evidence-Based and Rights-Centred Strategies for Mental Health Care across Europe" will take place from 9:00 – 13:30 on Saturday, 6 April 2019, followed by a light lunch. Please refer to pages 25–26 for the full programme.

First introduced in 2015, the EPA Forum will bring together EPA Council of National Association (NPA) members, EPA individual members, congress participants and European organisations, stakeholders and policy makers in the field of mental health and mental health care to present and discuss matters of European importance from the perspective of the EPA.









IMPLEMENTATION OF COMMUNITY-BASED MENTAL HEALTH CARE IN THE RECOVER-E PROJECT | Monday, April 8th, 2019 | 10:00 – 11:30

INFORMATION

RECOVER-E aims to ensure community-based mental health care in Bulgaria, Croatia, Macedonia, Montenegro, and Romania. Currently, comprehensive care is not available, functional, or tailored to these local contexts. RECOVER-E will implement care pathways to scale and narrow this gap.

CHAIRS | DR. IONELA PETREA, Head of Department Trimbos International and Project Leader for RECOVER-E | PROF. JERZY SAMOCHOWIEC, Head of the Department of Psychiatry at Pomeranian Medical University in Szczecin

SCHEDULE

10:00 - 10:15 | INTRODUCTION TO RECOVER-E | Dr. Ionela Petrea

Dr. Petrea will highlight the need for and transition to community-based mental health services in Central and Eastern Europe.

10:15 – 10:30 | RECOVER-E IN ZAGREB | Dr. Martina Rojnic Kuzman,
Assistant Professor of Psychiatry, Zagreb University Hospital Centre
Dr. Rojnic Kuzman will discuss the research and implementation of
community-based mental health services in Zagreb based on the F-ACT model
including unique situations that may impact care delivery.

10:30 – 10:45 | THE ROLE OF DUTCH SPECIALISTS | Dr. Rene Keet, Director Community Mental Health Service GGZ-NHN

Dr. Keet will outline the work of GGZ-NHN and specialists in the implementation of community-based mental health service teams.

10:45 - 11:30 | PLENARY DISCUSSION

This discussion will highlight forward steps for community-based mental health care in Central and Eastern Europe.



INFORMATION FOR PRESENTERS

Please check the congress mobile app or the online interactive programme for last-minute scheduling changes.

SPEAKERS' READY ROOM

 Saturday, 6 April
 12:00 – 18:30

 Sunday, 7 April
 7:00 – 18:30

 Monday, 8 April
 7:30 – 18:30

 Tuesday, 9 April
 7:30 – 14:30

ORAL PRESENTATIONS

DATA PRESENTATION:

If using a PowerPoint (or any other computer) presentation, please note you need to bring it on memory stick and load it on one of the congress computers in the Speakers' Ready Room at least 1 hour before the start of the session.

Please note that the congress computers in the session halls are being supplied with Office 2016 at least.

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is scheduled to take place during a coffee or lunch break prior to your session, at least 30 minutes before the start of the session - **even after checking it in the Speakers' Ready Room.**

Alternatively, you may supply your own laptop computer. In such a case please confirm that it has a HDMI socket for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is scheduled during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

This year speakers' presentations will also be available through the congress app. Speakers who have not already uploaded their presentations may do so in the Speakers' Ready Room.

Presentations will be available for viewings to all congress delegates in the app, which is updated once a day.

IMPORTANT NOTE FOR MAC USERS

In order to use Mac presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room:

- 1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC)
- 2. Insert pictures as JPG files (and not TIF, PNG or PICT these images will not be visible on a PowerPoint based PC)
- 3. Use a common movie format, such as AVI and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC)



Alternatively, you may use your own Mac laptop computer. In such a case please confirm you provide it with a **HDMI adaptor** for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is scheduled during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

PLEASE NOTE: IN COMPLIANCE WITH EACCME REQUIREMENTS ALL SPEAKERS ARE REQUESTED TO INCLUDE A SLIDE DISCLOSING CONFLICTS OF INTEREST AS THE SECOND SLIDE OF THEIR PRESENTATION.

E-POSTERS

Delegates will be granted access to an advanced e-Poster platform, which provides user-friendly access to all posters online, during and after the congress. The platform allows users to browse by e-Poster section and features educational tools such as searching for specific content, commenting on posters and directing questions to the authors. When permitted by the authors, posters will be available for download in PDF format. E-Poster viewing stations will be available in the Exhibition Area.

E-POSTER PRESENTATIONS

There are 85 e-Poster Presentation sessions that will take place on Sunday, Monday and Tuesday during the lunch and afternoon coffee breaks. Each session is chaired by a moderator and is composed of 10 to 20 presentations covering a wide range of topics.

Each presenter is given time for comments and questions after their presentation, stimulating constructive feedback and discussion. You are warmly invited to join the engaging sessions which will help your professional development.

All e-Posters presented in the e-Poster Presentation sessions will be on display for the duration of the congress.

Please note that on-site submissions will not be accepted.



For the comfort of the presenters and the audience, headsets will be provided in the Exhibition Area.

E-POSTER VIEWING

E-Posters will be available at the e-Poster stations at the congress, on the EPA 2019 website and App during the Congress and in an online archive. Viewers will be able to easily find and browse e-Posters and download the posters in PDF format when permitted by the presenter.

MOBILE APPLICATION, INTERNET & WIFI

MOBILE APPLICATION

Download the EPA 2019 interactive mobile app to your smartphone and portable devices to access all the information you will need during and after the congress:

- See the overview of sessions, speakers and exhibitors
- Create your own programme for the event, including bookmarking the sessions you wish to attend
- · Receive real-time updates
- Follow along with the speakers by viewing their presentations in real time during the sessions*. This feature also allows you to take notes and bookmark key content.
- * Valid in sessions for which the speaker has made his or her presentation available on the Congress App.

Download the EPA App now to enhance your congress experience! (available on the App Store or Google Play: EPA 2019)

CHARGING STATIONS

Charging stations are located in the Exhibition Area and are available during exhibition opening hours only.

- Electrical outlets and charging cables for most mobile phones and small tablets will also be available at this station.
- The EPA is not responsible for items that are misplaced or stolen.

Please do be considerate of fellow participants when using these facilities.



WIFI

Free internet is available to all congress participants in the congress venue. Please be aware that public WIFI capacity is always limited and therefore restricted to email and web browsing activity.

Network Name: **EPA042019** Password: **epa042019**



SOCIAL MEDIA

Please Tweet about the Congress using the hashtag **#EPA2019** and username @Euro_Psychiatry.

PHOTO CONTEST

The EPA is again holding a photo contest. Share your photos from EPA 2019 for a chance to win! Visit us on Facebook or Twitter **@Euro_Psychiatry** to learn more.



CME ACCREDITATION & CERTIFICATE OF ATTENDANCE

EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (UEMS/EACCME)

The 27th European Congress of Psychiatry is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net.

The 27th European Congress of Psychiatry is designated for a maximum of, or up to, 24 European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of *AMA PRA Category 1 Credits*TM. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA).

ROYAL COLLEGE OF PHYSICIANS & SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca.

EDUCATIONAL OBJECTIVES

After participating in this educational event, learners should be able to:

- Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
- Review the latest developments in diagnosis and treatment of bipolar disorders.
- Discuss new evidences and treatment of adult ADHD.
- Analyse the treatment of major psychiatric disorders.
- Enhance the discussion and exchange among European and international psychiatrists, and researchers as a means of further developing individual expertise.
- Discuss current developments in psychiatric epidemiology.
- Discuss the diagnosis and management of treatment resistant psychiatric disorders.
- Analyse the psychological perspective on mental health and mental disorder research in Europe.

TARGET AUDIENCE

EPA 2019 target audience includes expert clinical psychiatrists, researchers and leaders of stakeholder organisations in the field of mental health. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

CREDIT BREAKDOWN

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

Day	Maximum Credits
Saturday, 6 April	7
Sunday, 7 April	6
Monday, 8 April	6
Tuesday, 9 April	5
Total Credits:	24

TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

Before 7 May 2019:

- 1. Access the online system via any of the following
 - Visit the following link
 - www.surveymonkey.com/r/EPA2019Evaluation
 - Please note that web browsers Mozilla Firefox 2.X or higher, or Google Chrome are recommended
 - Visit the CME/CPD Accreditation page on the event website
 - Follow the link in the email sent at the end of the event
- 2. Complete the anonymous online evaluation
- 3. Complete the credit claim form and submit
- 4. The CME/CPD certificate will be available for download and/or print for your personal records



DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

• Disclosure information is available on the event website and also at the Faculty Desk in the registration area.

INDUSTRY SUPPORT DISCLOSURE

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organisations is made in the programme guide, on the event website, and with signage during the event.

- A list of all industry supporters is available in the Industry Support and Exhibition section at the back of the programme guide.
- Detailed programmes for all Industry Sessions are available on pages 148–151.

EPA COURSES

EPA Courses will be held throughout the congress, and pre-registration is required. EPA members can register for 2 courses for the price of 1. Please contact the Registration Desk for additional information regarding the availability of courses and registration. Participants are requested to present their course ticket at the entrance of the appropriate hall.

ACCREDITATION

The EPA Courses are accredited within the accreditation of the 27th European Congress of Psychiatry EPA 2019. EPA Courses are designated for a maximum of, or up to, 3 European CME credits (ECMEC) per course. These are to be claimed within the total number of CME credits claimed for EPA 2019, while respecting the maximum number of credits per day.

EARLY CAREER PSYCHIATRISTS' PROGRAMME

The Early Career Psychiatrists' (ECP) Lounge is situated in Pavilion 3 and is dedicated to Early Career Psychiatrists and Trainees, offering the opportunity for networking.

The Lounge will be open at the following times:

 Saturday, 6 April
 8:00 - 23:00

 Sunday, 7 April
 7:00 - 18:30

 Monday, 8 April
 7:30 - 18:30

 Tuesday, 9 April
 7:30 - 15:00

All ECP sessions take place in Hall F located next to the ECP Lounge.

ECP PROGRAMME

ECP PROGRAMME		
Clinical Case Discussion: Alcohol Use Disorders		
Training Workshop: 'Basic' Psychotherapy Case Discussion: A Requirement in the Training of Young Psychiatrists		
Symposium: Digital Mental Health: Hot Topics		
l		
Training Workshop: How to Start and Carry Out a Small Research Study Using Your Own Resources?		
Symposium: Mental Illness and Social Isolation: Why Does It Happen and How Can We Change It?		
Training Workshop: Transition from Institutionalised to Community-Based Care: How to Design Psychiatric Facilities?		
Debate: The Rise in Adolescent Suicide: Can It Be Fixed?		
l		
Training Workshop: How to Publish at the Early Career Stage?		
Training Workshop: Balancing Life, Career, Gender: Insights from Experts		



ABOUT THE EUROPEAN PSYCHIATRIC ASSOCIATION

The European Psychiatric Association (EPA) was founded in 1983. With active individual members in as many as 88 countries and 43 National Psychiatric Association Members who represent over 80,000 European psychiatrists, the EPA is the main association representing psychiatry in Europe. Its mission is to improve psychiatry and mental health care in Europe.

EPA members include leading experts in numerous fields. The EPA's activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. Together, EPA members contribute to the life of the association and to the development of psychiatry in Europe. Each member has the possibility to actively contribute to ongoing projects and play a key role in shaping the future of the association and its policies.

The EPA accomplishes its mission through the following activities:

- Annual European Congress of Psychiatry
- European Psychiatry journal
- EPA Courses, Summer School, Faculty Workshop and other forms of training Early Career Psychiatrists Committee and Programme
- Research Prizes and Scholarship Programme
- 22 Scientific Sections
- Cooperation with National Psychiatric Associations through EPA membership
- Guidance papers and position statements on related topics of interest
- Initiatives on improving ethical standards of psychiatric care and practice
- Collaborative activities in partnership with international organisations working in the field of psychiatry and mental health care.

For more information on EPA, visit www.europsy.net.

Please consult the EPA 2019 Mobile Application for further information on:

- EPA Committees
- EPA Sections
- EPA National Psychiatric Association Members
- EPA Administrative Meetings and EPA Section Meetings

EPA PRIZES AND AWARDS

One of the EPA's missions is to accompany Early Career Psychiatrists in their professional development. The Association proposes a panel of grants and prizes. The EPA is delighted to award the following prizes at the 27th European Congress of Psychiatry during the Opening Ceremony on Saturday, 6 April at 18:30 in Plenary Hall A. located in Pavilion 4.

2019 RESEARCH PRIZE WINNERS

Five Research Prizes of €2,000 each have been awarded to the following Early Career Psychiatrists working in Europe who published the best scientific papers in 2018:

Category 1:

Best paper published in European Psychiatry

Delfina Janiri (Italv)

"Psychopathological characteristics and adverse childhood events are differentially associated with suicidal ideation and suicidal acts in mood disorders"

Category 2:

Biological correlates and treatments of mental disorders

Luis Alameda (UK)

"Redox Dysregulation as a Link between Childhood Trauma and Psychopathological and Neurocognitive Profile in Early Psychosis Patients"

Category 3:

Child and adolescent psychiatry

Hélène Vulser (France)

"Early Variations in White Matter Microstructure and Depression Outcome in Adolescents With Subthreshold Depression"

Category 4:

Psychiatric epidemiology, social psychiatry and psychotherapeutic interventions in mental disorders

Pirathiv Kugathasan (Denmark)

"Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia"

Category 5:

Clinical psychopathology and refinement of psychiatric diagnostic categories

Daria Smirnova (Russia)

"Language Patterns Discriminate Mild Depression from Normal Sadness and Euthymic State"



2019 ECP SCHOLARSHIP PROGRAMME

The EPA Scholarship Programme provides a special grant including free congress registration for the European Congress of Psychiatry, travel expenses, hotel accommodation, complimentary registration for one EPA Course, invitation to the Early Career Psychiatrists' Luncheon and free EPA membership in 2019. The scholarship is available for early career psychiatrists who are either trainees or within 5 years of completion of specialist training in psychiatry and who are working in countries that form part of the World Health Organization Europe region.

The 2019 Scholarship Programme winners are:

Pavel Trančík, Czech Republic

Gamze Erzin, Turkey

Matthäus Fellinger, Austria

Tereza Gómez Alemany, Spain

Theodoros Koutsomitros, Greece

2019 EPA CONSTANCE PASCAL – HELEN BOYLE PRIZE FOR OUTSTANDING ACHIEVEMENT BY A WOMAN WORKING TO IMPROVE MENTAL HEALTH CARE IN EUROPE

The EPA launched this prestigious prize to publicly acknowledge and increase awareness of the outstanding achievements by women working to improve mental health care in Europe.

The prize is named in honour of Dr Helen Boyle, an Irish-British psychiatrist who was the first female President of the Medico-Psychological Association (later to become the Royal College of Psychiatrists), and Dr Constance Pascal, a Romanian doctor who was the first woman to qualify as a psychiatrist in France.



Laureate for 2019:

Professor Helen Killaspy, UK

2019 BEST E-POSTER PRIZE

After a thorough pre-congress review by Local Organising Committee Members, the top 10 e-Posters are awarded a prize of €300. Please check the App for updated information on the winners' names.

EPA 2019 SCIENTIFIC PROGRAMME OVERVIEW

The EPA 2019 Scientific Programme is composed of 5 main tracks; each track is constituted of a variety of Plenary and State of the Art sessions, Debates, Symposia, and Workshops:

- **Research Track** is composed of sessions with a focus on current research trends in psychiatry.
- Clinical / Therapeutic Track offers participants updated, state-of-the-art, clinical and therapeutic information which is based on research and linked to daily practice.
- **Educational Track** provides an update on developments in the field and the opportunity for exchange of ideas between participants and speakers.
- **European Track** deals with common issues for psychiatrists across Europe and will therefore be of particular interest for members of the National Psychiatric Societies/Associations.
- Mental Health Policy Track deals with principles and models for action aimed at promoting mental health.

Within each track, some sessions are part of the Early Career Psychiatrists' Programme (ECP). The EPA invites recent graduates to participate in these sessions, which are tailored to the needs of the early career psychiatrist.

The Scientific Programme will also include:

- **Oral Communications Sessions:** There are 14 Oral Communications Sessions classified by topic, in which the authors of selected outstanding abstracts will give a talk.
- Industry Supported Sessions: There are 7 Satellite Sessions organised by pharmaceutical companies in consultation with the Scientific Programme Committee. Learn more about the Satellite Symposia on pages 148–151.
- **E-Poster Presentations:** 1000+ outstanding posters will be presented at the 17 e-Poster stations in the Exhibition area throughout the duration of the Congress during lunch and afternoon breaks. Each e-Poster Presentation session is classified by topic and chaired by a moderator. For the comfort of the presenters and the audience, headsets will be provided in the Exhibition Area.
- **E-Poster viewing:** The e-Posters in display are classified by topic and they can be viewed on the 17 screen stations throughout the Congress.
- Ask the Expert Sessions: These sessions allow participants to meet in small groups with outstanding researchers and clinicians. The sessions, limited in number and taking place at round tables, are designed to facilitate informal discussion, allowing participants to present their questions and gain new perspective. Advance sign up is required. Please see the registration desk for details.
- S EPA Section Symposia, Workshops and EPA Courses
- Session requiring pre-registration
- Early Career Psychiatrists' Programme



Follow EPA on Social Media to access exclusive content, learn about EPA activities, exchange knowledge and network with colleagues around the globe.



#EPA2019



EUROPEAN PSYCHIATRIC ASSOCIATION

JOIN EPA FOR ONLY € 100 ANNUAL FEE

To become an individual member of the EPA, you are invited to complete an application form on the EPA website: https://www.europsy.net/become-a-member/.

THE ADVANTAGES OF EPA MEMBERSHIP:

LEARN

Keep informed about the latest scientific research and treatments

NETWORK

Integrate the network of Europear practitioners and researchers in Psychiatry

CONTRIBUTE

Get involved in the association and take an active part in the development of Psychiatry in Europe

ADVANCE

Accelerate your career and professional development

INFLUENCE


Have a voice and a role in shaping the future of the profession

MEMBER BENEFITS:

- Free electronic subscription to European Psychiatry journal
- Discounted registration fees for the annual European Congress of Psychiatry
- Preferential prices for EPA Courses
- An invitation to EPA General Assembly and right to vote (depending on membership category)
- Access to the EPA Extranet and member directory
- An invitation to join 21 scientific Sections
- Free monthly subscription to the EPA Minds Online newsletter

FIND OUT MORE AT:
WWW.EUROPSY.NET

WWW.EPA-CONGRESS.ORG



SCIENTIFIC PROGRAMME

SATURDAY 6 APRIL 2019





PSYCHIATRY
AND MENTAL
HEALTH: GLOBAL
INSPIRATIONS,
LOCALLY RELEVANT
ACTION

19[™] WPA WORLD CONGRESS OF PSYCHIATRY

LISBON, 21-24 AUGUST, 2019

www.wcp-congress.com/2019







REGISTER EARLY AND SAVE







SCIENTIFIC PROGRAMME SATURDAY, 6 APRIL 2019

9:00 - 13:30 HALL B

FPA Forum 2019

Implementing Comprehensive, Evidence-Based and Rights-Centred Strategies for Mental Health Care across Europe

9:00 Welcome and Introduction

The EU Contribution to Mental Health Policy and Transfer of Best Practices in Mental Health at EU Member States Level

Chairs: S. Galderisi (Italy)
P. Gorwood (France)

- 9:15 Research and Innovation in Mental Health S. Hogan (Belgium)
- 9:35 ROAMER and Horizon 2020: Priorities in Clinical Mental Health Research J.M. Haro (*Spain*)
- 9:55 EU-Compass for Action on Mental Health and Well-Being
 I. Petrea (*The Netherlands*)
- 10:15 Innovative Programmes, Practices and Policies for E-Mental Health M. Popovic (Luxembourg)
- 10:35 Discussion
- 10:55 Coffee Break

The Impact of the UN Convention on the Rights of Persons with Disabilities (CRPD) on Mental Health Policies, Research and Care

Chairs: W. Gaebel (Germany)

D. Wasserman (Sweden)

11:30 The CRPD - Report on the Right of Everyone to Enjoy the Highest Attainable Standard of Physical and Mental Health

D. Puras (Lithuania)

11:50 Mental Health, Standards of Care and Human Rights [BOLD]
D. Chisholm (Denmark)

12:10 The WPA Perspective
H. Herrman (Australia)

12:30 The Users' and the EPA Perspective
A. Nomidou (Belgium)

12:50 The Families' and the Carers' Perspective M. Walker (*Belgium*)

13:10 Discussion

13:35 EPA Forum Lunch



14:45 - 18:15





HALL F

EPA Course 1

Adult ADHD

Proposed by the EPA Section on Neurodevelopmental Disorders Across Lifespan (NDAL)

Course Director

E. Sobanski (Germany)

Course Co-Director

P. Asherson (United Kingdom)

Course Co-Director

J.A. Ramos-Quiroga (Spain)

Course Co-Director

S. Kooij (The Netherlands)

14:45 - 18:15



HALL G

EPA Course 2

An Introduction to CBT for Psychiatrists

Course Director

S. Moorey (United Kingdom)

14:45 - 18:15





HALL H

EPA Course 3

The Pharmacological Management of Psychosis and Mood Disorders in **Pregnancy and Lactation**

Proposed by the EPA Section on Women, Gender and Mental Health

Course Director

A. Wieck (United Kingdom)

Course Co-Director

I. Jones (United Kingdom)







HALL I

EPA Course 4

The ABCs of Neuropsychiatry for Psychiatrists

Proposed by the EPA Section on Old Age Psychiatry

Course Director

D. Okai (United Kingdom)

Course Co-Director

I. Koychev (United Kingdom)

Course Co-Director

C. Hanon (France)

14:45 - 18:15



HALL J

EPA Course 5

How to Write a Paper and Publish it in Scientific Journals

Course Director

A. Fiorillo (Italy)

Course Co-Director

R. Heun (United Kingdom)

14:45 - 18:15



HALL K

EPA Course 6

Electroconvulsive Therapy: A Course for Prescribers

Course Director

D. McLoughlin (Ireland)

Course Co-Director

P. Sienaert (Belgium)

Course Co-Director

C. Kellner (USA)



14:45 - 18:15





HALL L

EPA Course 7

Screening Cognitive Impairments in Psychosis Using the Cognitive Assessment

Proposed by the EPA Section on Schizophrenia

Course Director

J. Ventura (USA)

Course Co-Director

A. Mucci (Italy)

14:45 - 18:15



HALL M

EPA Course 8

Personalised Psychopharmacotherapy Using Therapeutic Drug Monitoring and Genotyping

Course Director

C. Hiemke (Germany)

Course Co-Director

G. Laux (Germany)

16:15 - 16:45

EXHIBITION HALL

Coffee Break



Starting in MAY 2019

Introduction to Motivational Interviewing

Led by • Guy Undrill

Consultant psychiatrist and MI instructor - UK





→ Visit europsy.net for more info





SCIENTIFIC PROGRAMME

SUNDAY 7 APRIL 2019



EUROPEAN PSYCHIATRIC ASSOCIATION

12 > 15 **SEPTEMBER 2019**

Strasbourg, France





ABCs of **Psychotherapy**

9TH EPA SUMMER SCHOOL





APPLY NOW

on the EPA website and join us at the next **Summer School!**

"It was a fulfilling experience and I have achieved so much in so little time. I have already started to use the skills I learned in my daily practice and I will continue to do everything I can to improve them"

2018 Scholar







f 🟏 in europsy.net



SCIENTIFIC PROGRAMME SUNDAY, 7 APRIL 2019

8:00 - 9:30 HALL A

Symposium

Lifestyle Modifications for Treatment of Major Psychiatric Disorders: Current and Future Perspectives

Chairs: J. Samochowiec (*Poland*)
P. Falkai (*Germany*)

- 8:00 Non-Pharmacological Treatment Options in Schizophrenia: Beyond Psychotherapy
 - P. Falkai (Germany)
- 8:20 Potential Effects of Physical Activity on Psychosis
 - B. Stubbs (United Kingdom)
- 8:40 Dietary Factors in the Treatment of Major Psychiatric Disorders: Focus on Essential Fatty Acids and Gluten
 - H. Karakula-Juchnowicz (Poland)
- 9:00 The Role of Gut Microbiota in Major Psychiatric Disorders: Future Perspectives
 - T. Dinan (Ireland)
- 9:20 Discussion

8:00 - 9:30 HALL B

Symposium

Mass Violence, Radicalisation and Terrorism: Relation with Mental Health and Role of Psychiatric Professionals

Chairs: L. Küey (*Turkey*)
T. Kurimay (*Hungary*)

8:00 Systematic Litterature Review on Mass Violence, Radicalisation and Mental Health

B. Misiak (Poland)

8:20 The Danger of Radicalisation of Refugees, Asylum Seekers and Displaced Persons: Cultural Influence

M. Schouler-Ocak (Germany)

8:40 Mental Illness and Terrorism

E. Jones (United Kingdom)

9:00 Migration, Violence, and the Role of Psychiatry in Europe

D. Bhugra (United Kingdom)

9:20 Discussion

34



8:00 - 9:30 S HALL C

Workshop

Neuroimaging in the Elderly

Proposed by the EPA Section on Old Age Psychiatry and the EPA Section on Neuroimaging

Chairs: C. Hanon (France)
P. Brambilla (Italy)

8:00 Neuroimaging Biomarkers of Further Cognitive Decline in Late-Life Depression : Evidences and Perspectives

G. Robert (France)

8:16 Amyloid Imaging in Late-Life Depression

F. Bouckaert (Belgium)

8:32 Functional Imaging of Episodic Memory in Dementia

R. Heun (United Kingdom)

8:48 Imaging of Late Schizophrenia

U. Volpe (Italy)

9:04 Predictive Response Factors of Repetitive Transcranial Magnetic Stimulation in Drug-Resistant Depression in the Elderly

B. Calvet (France)

9:20 Discussion

Symposium

Early Intervention in Psychoses: the State of the Art

Proposed by the EPA Section on Schizophrenia

Chairs: S. Galderisi (Italy)
W. Gaebel (Germany)

8:00 European Status and Perspectives on Early Detection and Intervention in At-Risk Mental State and First Episode Psychosis

A. Riecher-Rössler (Switzerland)

8:20 Perspectives and Challenges for Early Intervention Services in Italy
S. Tosato (Italy)

8:40 Long-Term Effects of Early Intervention Programmes: Saving Young People's Lives

M. Nordentoft (Denmark)

9:00 Dynamic Symptom Networks for the Prediction of Onset and Progression of Psychosis: Mapping Individual Routes of Risk and Resilience (MIRORR) Study

J. Wigman (The Netherlands)

9:20 Discussion

8:00 - 9:30 HALL E

Debate

Sexual Addiction: Does it Exist?

Chair: F. Thibaut (France)

8:00 Pro

M. Potenza (USA)

8:30 Con

A. Weinstein (Israel)

9:00 Discussion



8:00 - 9:30 HALL F

Workshop

Divergent Perspectives on the Psychopathology and Management of Borderline Personality Disorder

Chairs: J.N. Kjær (Denmark)
P. Trančík (Czech Republic)

8:00 A Nationwide Study of the Diagnostic Trajectory of Patients with Borderline Personality Disorder

J.N. Kjær (Denmark)

- 8:16 Comorbid Personality Disorders in Patients with First Episode Psychosis K.Y. Ban (*United Kingdom*)
- 8:32 Examination of Anamolous Self-Experience in Borderline Personality Disorder

M. Zandersen (Denmark)

8:48 Diagnosing Borderline Personality Disorder: A Clinical Perspective from an Early Career Psychiatrist

T.M. Gondek (Poland)

9:04 Management and Treatment of Borderline Personality Disorder in Adolescents and Young Adults

E. El-Higaya (Ireland)

Workshop

Setting and Achieving Standards in Women Mental Health

Proposed by the EPA Section on Women, Gender and Mental Health

Chairs: A. Wieck (United Kingdom)
N. Semenova (Russia)

- 8:00 Universal Access of Childbearing Women with Severe Mental Illness to Specialist Care: How Can this be Achieved ?
 - G. Berrisford (United Kingdom)
- 8:16 Quality Standards for Perinatal Mental Health Services: an Example from the UK
 - E. McDonald (United Kingdom)
- 8:32 The Consensus Standards for the Diagnosis and Treatment of Premenstrual Disorders by the International Society for Premenstrual Disorder
 - E. Eriksson (Sweden)
- 8:48 How much Progress Have We Made with Setting Care Standards for Women in Mental Health Services?
 - L. Vavrusova (Slovak Republic)
- 9:04 How Can the WPA Support the Implementation of Standards in Women Mental Health?
 - N. Semenova (Russia)
- 9:20 Discussion



8:00 - 9:30 HALL H

Symposium

Epigenetic and Neuroendocrine Alterations Mediating the Association Between Exposure to Stress During Ontogenic Windows of Development and Risk for Psychiatric Disorders

Chairs: L. Fañanás (Spain) F. Cirulli (Italy)

- 8:00 Stress During Pregnancy and its Role for the Toddler's Neurodevelopment M. Deuschle (*Germany*)
- 8:20 Preterm Behavioural Epigenetics: DNA Methylation and Telomere Length Regulation as Biomarkers of Early Adversities and Developmental Risk in Very Preterm Infants

L. Provenzi (Italy)

8:40 Proximal Exposure to Severe Childhood Maltreatment and HPA Axis Deregulation in Young Individuals

H. Palma-Gudiel (Spain)

9:00 Embedding of Chronic Stress in the Epigenome

A. Zannas (USA)

9:20 Discussion

8:00 - 11:30 HALL I

EPA Course 9

Ethical Dilemmas in Clinical Psychiatry and Education

Course Director

N. Sartorius (Switzerland)

Course Co-Director

D. Wasserman (Sweden)

8:00 - 11:30 HALL J

EPA Course 11

Transgender Care Within Psychiatry: What to Know and How to Teach

Course Director

J.M. Bostwick (USA)

Course Co-Director

E. Bieber (USA)

8:00 - 11:30 HALL K

EPA Course 12

Clozapine: The Art of Prescribing

Course Director

D. Cohen (The Netherlands)

Course Co-Director

S. Farooq (United Kingdom)

9:30 - 10:00 EXHIBITION HALL

Coffee Break, e-Poster Viewing & Visit the Exhibition



10:00 - 11:30

S

HALL A

Symposium

Virtual Reality in the Assessment and Treatment of Psychotic Disorders

Proposed by the EPA Section on Schizophrenia

Chairs: S. Galderisi (Italy)

M. Nordentoft (Denmark)

- 10:00 Virtual Reality in the Treatment of Psychosis: Its Role in Early Detection and Treatment Programmes
 - M. Nordentoft (Denmark)
- 10:20 Virtual Reality in the Assessment and Treatment of Paranoid Ideation W. Veling (The Netherlands)
- 10:40 Autonomic Deregulation in Psychosis: Wearable Device and Assessment of Physiological Parameters
 - M. Cella (United Kingdom)
- 11:00 AVATAR Therapy for Distressing Voices
 - P. Garety (United Kingdom)
- 11:20 Discussion

Symposium

Suicidal Behaviour in Immigrants, Refugees, Asylum Seekers and Ethnic Minorities

Proposed by the EPA Section on Suicidology and Suicide Prevention and the EPA Section on Cultural Psychiatry

Chairs: M. Sarchiapone (Italy)
M. Schouler-Ocak (Germany)

- 10:00 Migrant's Suicidal Behaviours: a Transcultural Perspective C. Gramaglia (*Italy*)
- 10:20 Suicidal Ideation Are Displaced People More at Risk? M. Schouler-Ocak (Germany)
- 10:40 Effects of Gender and Generation on Suicidal Ideation and Suicidal Risk in Migrants and Non-Migrants in Germany: Findings from a Household Survey
 - M. Aichberger (Germany)
- 11:00 Suicidal Behaviour Among Black and Minority Ethnic Groups in London D. Bhugra (United Kingdom)
- 11:20 Discussion



10:00 - 11:30 HALL C

Symposium

Biomarkers: the Future of Diagnosis in Psychiatry?

Chairs: A. Szulc (Poland)
M. Ratajczak (USA)

- 10:00 Can We Diagnose Schizophrenia with a Blood Test?
 - A. Szulc (Poland)
- 10:20 Sterile Inflammation of Brain, due to Activation of Innate Immunity, as a Culprit in Psychiatric Disorders
 - M. Ratajczak (USA)
- 10:40 Understanding Heterogeneity and Variability in Brain Imaging Phenotypes of Psychosis
 - S. Frangou (USA)
- 11:00 Genetic Markers and Stem Cells in Psychiatry
 - J. Samochowiec (Poland)
- 11:20 Discussion

Symposium

Social Evaluation and Emotion Regulation in Eating Disorders: Advances in the Management of Anorexia and Bulimia Nervosa

Proposed by the EPA Section on Eating Disorders

Chairs: P. Monteleone (Italy)

J. Treasure (United Kingdom)

10:00 Emotion Regulation and Social Interaction in Eating Disorders: from Clinical to Neurobiological Approaches

F. Fernández-Aranda (Spain)

10:20 A Multilevel Approach to the Effects of Social Evaluation Exposure: Which Responses in Eating Disorders?

A. Monteleone (Italy)

10:40 Novel Neuropeptides in Eating Disorders

M. Tyszkiewicz-Nwafor (Poland)

11:00 The Improvement of Social Cognitive and Neurocognitive Functioning in Anorexia Nervosa throughout the Integrative Model of Psychotherapy

K. Kucharska (Poland)



10:00 - 11:30 HALL E

Symposium

DSM, ICD, and RDoC: Quo Vadis Classification?

Chairs: W. Gaebel (Germany)

J. Beezhold (United Kingdom)

- 10:00 DSM and the Categorical-Dimensional Debate
 - J. Van Os (The Netherlands)
- 10:20 Utility as the Mainstay of ICD-11 and Future Revisions?

G. Reed (Switzerland)

- 10:40 Why the Clinical Utility of DSM and ICD is Intrinsically Limited and How We Can Use New Approaches to Complement Them M. Maj (Italy)
- 11:00 What is the Role of Clinical Psychopathology in Future Classification?
 W. Gaebel (Germany)
- 11:20 Discussion

10:00 - 11:30 ECP HALL F

ECP Clinical Case Discussion

Alcohol Use Disorders

Chairs: G. Sampogna (Italy)

M. Delic (Slovenia)

- 10:00 Southern European Perspectives
 - D. Quattrone (United Kingdom)
- 10:26 Western European Perspectives
 W. Van den Brink (The Netherlands)
- 10:52 Eastern European Perspectives

N. Waszkiewicz (Poland)

11:18 Discussion

Workshop

Online Training Resources for Psychiatric Trainees and Early Career Psychiatrists in Europe

Proposed by the EPA Section on TeleMental Health

Chairs: C. Hanon (France)
M. Filip (Poland)

10:00 The Young Psychiatrist's Academy: Online Tool to Improve Training in Poland

T.M. Gondek (Poland)

10:13 Online Tools for Psychiatric Training Produced by the Central Region of Denmark

J.N. Kjær (Denmark)

10:26 Online Learning Tools for Psychiatric Trainees in Spain H. Saiz Garcia (Spain)

10:39 The EPA's 1st MOOC about CBT: Insight from the Teacher S. Moorey (United Kingdom)

10:52 More than 6400 Participants: Who are They and How Could We Improve their Experience

N. Arnaoutoglou (United Kingdom)

11:05 Online Training Resources in Psychiatry: Which Experience Could We Take from Them?

T. Gargot (France)

11:18 Discussion



10:00 - 11:30 HALL H

Joint Symposium with the ECNP

What Will be the Impact of Digital Technology on the Practice of Clinicians in Psychiatry?

Chairs: P. Gorwood (France)
C. Arango (Spain)

10:00 The Potential Clinical Use of Body-Swapping in Virtual Reality

C. Brewin (United Kingdom)

10:30 Shaping the Future: Using Digital Technologies to Support New Treatment Pathways in Psychiatry

G. Dawson (United Kingdom)

11:00 Deep-Learning and Machine-Learning Applications to Identify Multivariate Biomarkers in Psychiatry

A. Meyer-Lindenberg (Germany)

11:30 - 11:45 EXHIBITION HALL

Short Break

11:45 - 12:30 HALL A

Plenary Lecture

Talking to Your Voices Might Help: the Use of Avatars in the Treatment of Psychosis

Chair: S. Galderisi (Italy)

- 11:45 Talking to Your Voices Might Help: the Use of Avatars in the Treatment of Psychosis
 - P. Garety (United Kingdom)

12:30 - 13:15 EXHIBITION HALL

Lunch Break, e-Poster Presentations & Visit the Exhibition

15:00 - 16:30 HALL A

Presidential Symposium

Investing Early in Mental Health Pays Off Later in Life

Chairs: P. Gorwood (France)

E. Sorel (USA)

15:00 Perinatal TOTAL Health

E. Sorel (USA)

- 15:20 Improving Mental Health by Targeting Early Life Epochs in Africa
 O. Gureje (Nigeria)
- 15:40 Improving Mental Health by Targeting Early Life Epochs in Europe G. Zalsman (Israel)
- 16:00 Improving Mental Health by Targeting Early Life Epochs in Asia
 A. Javed (United Kingdom)
- 16:20 Discussion



15:00 - 16:30 HALL B

Symposium

New Challenges in the Prevention and Treatment of Mental Disorders in the Peripartum Period

Chairs: A. Riecher-Rössler (Switzerland)

F. Thibaut (France)

15:00 New Challenges in the Prevention of Mental Disorders in the Peripartum Period

A. Riecher-Rössler (Switzerland)

15:25 New Challenges in the Psychopharmacology of Mental Disorders in the Peripartum Period

A.L. Sutter-Dellay (France)

15:50 New Challenges in the Treatment of Addiction in the Peripartum Period F. Thibaut (France)

16:15 Discussion

15:00 - 15:45 HALL C

State of the Art

Adaptive Brain Plasticity Allowing Resilience to Mood Disorders

Chair: L. Krabbendam (The Netherlands)

Adaptive Brain Plasticity Allowing Resilience to Mood Disorders

S. Frangou (USA)

15:45 - 16:30 HALL C

State of the Art

Successfully Predicting Transition to Manifest Mental Disorders from at-Risk States: the Machine Learning Approach

Chair: G. Dom (Belgium)

Successfully Predicting Transition to Manifest Mental Disorders from at-Risk States: the Machine Learning Approach

N. Koutsouleris (Germany)



15:00 - 16:30 HALL D

Symposium

The New Tools for the Assessment of Negative Symptoms in Schizophrenia

Chairs: A. Mucci (Italy)
S. Dollfus (France)

- 15:00 Construct Validity of the Brief Negative Symptom Scale (BNSS) and Relationship with Outcome in ENI Schizophrenia pan-European Study A. Mucci (Italy)
- 15:20 Self-Assessment of Negative Symptoms: Interest and Validity in Schizophrenia

S. Dollfus (France)

- 15:40 Negative Symptoms and Cognitive Deficits in Schizophrenia in the ENI Schizophrenia pan-European Study
 A. Hofer (Austria)
- 16:00 Polish Experiences with the BNSS and SNS Scales

J. Rybakowski (Poland)

Workshop

Making Sense of Suicide Risk Prevention: From Childhood Adversities to Clinical Judgement

Proposed by the EPA Section on Suicidology and Suicide Prevention

Chairs: M. Pompili (Italy)
X. Gonda (Hungary)

- 15:00 Crisis Intervention, Suicide and Childhood Adversities
 - A. Plaza Estrade (Spain)
- 15:16 Childhood Trauma, Dimensions of Psychopathology and the Clinical Expression of Bipolar Disorders
 - B. Etain (France)
- 15:32 From Patient Suicide to Suicide Risk Formulation
 - M. Pompili (Italy)
- 15:48 Exploring the Source of Discrepancy in Suicidal Rates Across Europe: Where do we Stand?
 - K. Fountoulakis (Greece)
- 16:04 Psycho-Social Factors in Suicide Risk
 - Z. Rihmer (Hungary)
- 16:20 Discussion



15:00 - 16:30 ECP HALL F

ECP Training Workshop

'Basic' Psychotherapy Case Discussion: A Requirement in the Training of Young Psychiatrists

Chairs: C. Hanon (France)

K. Koelkebeck (Germany)

15:00 'Basic' Psychotherapy: a Requirement in the Formation of Young Psychiatrists

G. Stanghellini (Italy)

16:20 Discussion

15:00 - 16:30 HALL G

Workshop

Mental Health Reforms in Eastern European Countries: Achievements and Challenges

Chairs: S. Galderisi (Italy)

W. Gaebel (Germany)

- 15:00 Assessing the Bulgarian Mental Health System: Learning from the Process H. Killaspy (United Kingdom)
- 15:20 Bulgarian Mental Health Reform: Recommendations from the European Psychiatric Association Expert Review
 - J. Beezhold (United Kingdom)
- 15:40 Presentation of Slovenian Mental Health Reform: Assessment of Needs and Opportunities

V. Švab (Slovenia)

- 16:00 Mental Health Reform: How Should Policy Makers Act?
 - J. M. Zakotnik (Slovenia)
- 16:20 Discussion

15:00 - 16:30 HALL H

Oral Communications 1

Anxiety Disorders and Somatoform Disorders / Neuroscience in Psychiatry / Obsessive-Compulsive Disorder/ Psychosurgery & Stimulation Methods (ECT, TMS, VNS, DBS)

Chair: S. Murawiec (Poland)

15:00 BIOLOGICAL MOTION PROCESSING IN PATIENTS WITH SCHIZOPHRENIA: A HIGH-DENSITY EEG EVENT RELATED POTENTIAL STUDY

M. Baradits (Hungary)

15:11 SPECTRAL ANALYSIS OF MAGNETOENCEPHALOGRAPHIC (MEG) CORRELATES OF, ANXIETY, AND THE EFFECT OF METHYLPHENIDATE, A POSSIBLE DISTINCTION BETWEEN PATIENTS SUFFERING FROM ADHD AND CONTROLS

Y. Bloch (Israel)

- 15:22 COMPULSIONS PREDICT PSYCHOLOGICAL DISTRESS THROUGH OBSESSIONS: EXPLORATORY STUDY IN A NON-CLINICAL SAMPLE C. Cabacos (Portugal)
- 15:33 AS ANXIOUS AS A VERTIGO PATIENT? COGNITIVE-BEHAVIOURAL GROUP THERAPY IN PATIENTS WITH ANXIETY DISORDER AND FUNCTIONAL DIZZINESS AN FMRI STUDY

A. Chrobok (Germany)

15:44 RECONSTRUCTION OF THE GLOBAL NEURAL NETWORK WITH THE APPLICATION OF MINIMUM SPANNING TREE IN FIRST-EPISODE SCHIZOPHRENIA PATIENTS AND ITS ASSOCIATIONS WITH COGNITIVE SPEED AND VARIABILITY

P. Krukow (Poland)

15:55 WELL-BEING OF MOTHERS WITH SEVERELY ACUTE
MALNOURISHED CHILDREN IN FACE OF ADVERSITIES IN SAPTARI
DISTRICT - NEPAL DURING 2015-2016

K. Le Roch (France)

15:06 FMRI EVALUATION OF DEEP BRAIN STIMULATION IN OBSESSIVE-COMPULSIVE DISORDER

M. Naesström (Sweden)

16:17 NEUROPSYCHOLOGICAL PERFORMANCE IN BASIC SYMPTOMS POSITIVE INDIVIDUALS VS GENERAL ADOLESCENT POPULATION P. Švancer (Czech Republic)



15:00 - 16:30 HALL I

Workshop

Ethical Challenges Are an Unavoidable Part of Practice in Psychiatry: How Do We Deal With That in the Best Possible Way?

Chairs: D. Wasserman (Sweden)
L. Vavrusova (Slovak Republic)

15:00 Ethical Dilemmas in Different Cultural Contexts

N. Sartorius (Switzerland)

15:20 Ethics in Communication with Families to Patients with the First Episode of Psychosis

L. Vavrusova (Slovak Republic)

15:40 Declaration of Geneva and its Consequences for the Psychiatrist

R. J. Van Der Gaag (The Netherlands)

16:00 End of the Life Care, Ethical Considerations

D. Wasserman (Sweden)

15:00 - 16:30 HALL J

Oral Communications 2

Bipolar Disorders / E-mental Health / Consultation Liaison Psychiatry and Psychosomatics

Chairs: J. Heitzman (Poland)

P. Gosek (Poland)

15:00 VALIDATION OF MOBILE DEVICE USE FOR THE EVALUATION OF SUICIDALITY

E. Chan (Canada)

15:10 COMPARISON OF PSYCHOLOGICAL AND PHYSICAL SYMPTOMS IN PATIENTS WITH NON-CARDIAC-ATYPICAL CHEST PAIN ACCORDING TO PRESENCE OR ABSENCE OF ALEXITHYMIA

Y.M. Jae (Republic of Korea)

15:20 PERSONALITY CHANGES FOLLOWING HEART TRANSPLANTS: CAN EPIGENETICS EXPLAIN THESE TRANSFORMATIONS?

M. Liester (USA)

15:30 PERSONALITY TRAITS AND THE RISK OF INCIDENT (HYPO)MANIA: A 9-YEAR LONGITUDINAL COHORT STUDY

R. Mesbah (The Netherlands)

15:40 UPDATED META-ANALYSIS AND MODERATOR ANALYSIS OF DEPREXIS, AN ELECTRONIC COGNITIVE BEHAVIOURAL THERAPY FOR DEPRESSION

B. Meyer (Germany)

15:50 DEPRESSIVE FEATURES ARE RELATED TO HIGHER INFLAMMATORY MARKERS IN A SAMPLE OF EUTHYMIC PATIENTS WITH BIPOLAR DISORDER: A FOCUS ON GENDER DIFFERENCES

E. Muñoz (Spain)

16:00 MINDFULNESS-BASED INTERVENTION THROUGH A SMARTPHONE APPLICATION VERSUS MINDFULNESS-BASED STRESS REDUCTION (MBSR) PROGRAMME IN HEALTHCARE STUDENTS: A RANDOMISED CONTROLLED TRIAL

A. Orosa Duarte (Spain)

16:10 SEARCH FOR POTENTIAL MARKERS OF BIPOLAR DISORDER USING PROTEOMIC METHODS.

A. Seregin (Russia)





16:20 THE EFFECT OF HPA AXIS FUNCTIONING ON VISUAL MEMORY IN BIPOLAR DISORDER

K. Tournikioti (Greece)

15:00 - 16:30

EXHIBITION - ASK THE EXPERTS

Ask the Experts 1

ADHD: a Diagnostic Challenge

E. Sobanski (Germany)

Psychiatry as a System Neuroscience

P. Falkai (Germany)

Psychiatry and Cultural Challenges

D. Bhugra (United Kingdom)

Understanding PTSD

J. Zohar (Israel)

The "Immune Gate" and Psychopathology

A. Szulc (Poland)

P. Gałecki (Poland)

Psychiatry and Sexuality

E. Bieber (USA)

How to Work Effectively in Intercultural Care

S. Farooq (United Kingdom)

16:30 - 17:00

EXHIBITION HALL

Coffee Break, e-Poster Presentations & Visit the Exhibition

17:00 - 18:30 HALL A

Debate

Should the UHR Paradigm for Transition to Mental Disorder be Abandoned?

Chair: A. Riecher-Rössler (Switzerland)

17:00 Pro

J. Van Os (The Netherlands)

17:30 Con

F. Schultze-Lutter (Germany)

18:00 Discussion

17:00 - 18:30



HALL B

Symposium

Adolescents' Non-Suicidal Self-Injury

Proposed by the EPA Section on Child and Adolescent Psychiatry

Chairs: J. Balazs (Hungary)
G. Zalsman (Israel)

- 17:00 Potential Links Between Suicide and Non-Suicidal Self-Injury
 - G. Zalsman (Israel)
- 17:25 Risk Factors of Adolescents' Non-Suicidal Self-Injury
 - J. Balazs (Hungary)
- 17:50 Treating Adolescents with Suicidal and Non-Suicidal Self-Injury: What Works?

L. Mehlum (Norway)

18:15 Discussion



17:00 - 18:30 HALL C

Symposium

Paternal Depression in the Postpartum and Beyond: Diagnosis, Risk Factors and Consequences for Child Development

Chairs: M. Melchior (France)
A. Nakamura (France)

- 17:00 Depression and Parental Stress among Swedish Fathers in the Postnatal Period: Screening and Working Through the Help-Seeking Barriers
 - E. Psouni (Sweden)
- 17:20 Identifying Risk Factors for Paternal Depression in the Perinatal Period: Data from the ELFE Cohort Study
 - A. Nakamura (France)
- 17:40 Depression and Playfulness in Fathers and Young Infants: A Matched Design Comparison Study
 - V. Sethna (United Kingdom)
- 18:00 Paternal Depression and Emotional and Behavioural Problems in Middle Childhood the Role of Father Involvement
 - J Van der Waerden (France)
- 18:20 Discussion

Workshop

Treatment of Comorbid Psychiatric Disorders: How Do We Deal With

Proposed by the EPA Section on Child and Adolescent Psychiatry

Chairs: M. Wojnar (Poland)

A. Batalla (The Netherlands)

17:00 Treating Comorbid Depression and Alcohol Use Disorder: Do We Know How and When to Start?

A. Jakubczyk (Poland)

17:20 Substance Use Disorders and PTSD

G. Dom (Belgium)

17:40 ADHD and Comorbid Substance Use Disorders: Mechanisms and Clinical Implications

A. Schellekens (The Netherlands)

18:00 Comorbid Psychosis and Addiction: Practical and Novel Approaches

A. Batalla (The Netherlands)



17:00 - 18:30 HALL E

Workshop

New Challenges in Education in Psychiatry

Chairs: A. Fiorillo (Italy)
W. Gaebel (Germany)

- 17:00 Where Are We on the Long Way of Harmonisation of Psychiatric Training in Europe?
 - M. Hermans (Belgium)
- 17:13 Education in Psychiatry in Europe: the Contribution of the European Psychiatric Association
 - C. Hanon (France)
- 17:26 Choosing an Academic Career in Psychiatry: Results from a Survey of the World Psychiatric Association
 - G. Sampogna (Italy)
- 17:39 Education in Psychiatry 2.0: Views from Early Career Psychiatrists and Psychiatric Trainees
 - O. Kazakova (Belarus)
- 17:52 The European Examination in General Cardiology
 - C. Plummer (United Kingdom)
- 18:05 Training Psychiatrists in the New Millennium
 - D. Bhugra (United Kingdom)
- 18:18 Discussion

17:00 - 18:30 ECP HALL F

ECP Symposium

Digital Mental Health: Hot Topics

Chairs: U. Volpe (Italy)

M. Pinto da Costa (Portugal)

17:00 Digital Innovation in Mental Health

J. Zohar (Israel)

17:20 What Is Digital Phenotyping in Mental Health Care?

A. Raballo (Italy)

17:40 Psychotherapy and New Communication Technologies

T. Frančišković (Croatia)

18:00 Online and Offline Training Opportunities for Psychiatric Trainees

P. Trančík (Czech Republic)

C. So (France)



17:00 - 18:30 HALL G

Joint Symposium with the Hosting NPA

Psychiatry in Transition: the European Experience

Chairs: P. Gorwood (France)
A. Szulc (Poland)

- 17:00 Psychiatry in Transition: Towards a Reconceptualisation of Mental Health and Mental Health Disorders
 - S. Galderisi (Italy)
- 17:20 Identity of Psychiatry in Europe
 - P. Falkai (Germany)
- 17:40 Transition in Psychiatry: Myths and Reality
 - J. Samochowiec (Poland)
- 18:00 Reform of Psychiatry in Poland: if We're Going to Do This, it's Now or Never
 - A. Szulc (Poland)
- 18:20 Discussion

17:00 - 18:30 HALL H

Symposium

Metabolic Syndrome in Psychiatry: Recognition and Management of Psychotropic Drug-Induced Metabolic Effects

Chairs: C.B. Eap (Switzerland)
C.U. Correll (USA)

17:00 Metabolic Syndrome in Psychiatry: an Overview

C.U. Correll (USA)

17:20 The Influence of Exercise on Body Composition and the Metabolic Syndrome in Severe Mental Illness

K. Kahl (Germany)

17:40 Clinical Determinants of Metabolic Syndrome Induced by Psychotropic Drugs

C.B. Eap (Switzerland)

18:00 Genetic Determinants of Metabolic Syndrome Induced by Psychotropic Drugs

EPA 2019

M. Maciukiewicz (Canada)



17:00 - 18:30 HALL I

Symposium

All Psychiatrists Are Medical Doctors... Hope That They Have Not Forgotten Their Hippocratic Pledge

Chairs: N. Sartorius (Switzerland)

J. Beezhold (United Kingdom)

- 17:00 The 2017 Revised Version of the Declaration of Geneva
 - R. J. Van Der Gaag (The Netherlands)
- 17:20 Ethical Aspects of Patient's Autonomy in Cases of Suicidal or Dangerous Behaviour
 - M.E.Jan Wise (United Kingdom)
- 17:40 Medical Secrecy in Psychiatry: Boundaries, Safeguards and Limits M. Martin Carrasco (Spain)
- 18:00 Situations in Which Physicians Should Take the Stand of Opposition N. Sartorius (Switzerland)
- 18:20 Discussion

17:00 - 18:30 HALL J

Oral Communications 3

Epidemiology and Social Psychiatry / Psychoneuroimmunology / Sleep Disorders & Stress

Chair: M. Talarowska (Poland)

17:00 INFLAMMATION AND THE OCCURRENCE OF DELIRIUM IN ACUTELY ILL OLDER MEDICAL INPATIENTS

D. Adamis (Ireland)

17:08 THE PREVALENCE OF LONELINESS AND ITS ASSOCIATION WITH MORTALITY AMONG OLDER ADULTS IN LATIN AMERICA, CHINA, AND INDIA: A CROSS-CULTURAL STUDY

Q. Gao (United Kingdom)

17:16 ATYPICAL LONG-ACTING INJECTABLES DECREASE MORTALITY RISK COMPARED TO OTHER ANTIPSYCHOTICS

J. Grabowski (Poland)

17:24 EVOLUTION OF ANTI-NMDA RECEPTOR ENCEPHALITIS CLINICAL FEATURES IN ADULTS

R. Gurrera (USA)

17:32 CLINICAL PROGRESSION OF ANTI-NMDA RECEPTOR ENCEPHALITIS IN CHILDREN AND ADOLESCENTS

R. Gurrera (USA)

17:40 SLEEP DISTURBANCE IN HUNTINGTON'S DISEASE IN RELATION TO DEPRESSIVE DISORDER

K. Gustaw-Rothenberg (USA)

17:48 CLINICAL CHARACTERISTICS OF MAJOR DEPRESSIVE DISORDER AMONG NORTH KOREAN DEFECTORS.

H. Lee (Republic of Korea)

17:56 PAEDIATRIC PROLONGED-RELEASE MELATONIN FOR SLEEP IN CHILDREN WITH AUTISM SPECTRUM DISORDER: IMPLICATIONS FOR CHILD BEHAVIOUR AND CAREGIVER'S QUALITY OF LIFE

A. Maras (The Netherlands)

18:04 COMPARATIVE STUDY OF OBSTRUCTIVE SLEEP APNEA SYNDROME PATIENTS WITH HEALTHY VOLUNTEERS IN TERMS OF CHILDHOOD TRAUMAS AND DISSOCIATIVE EXPERIENCES

A. Nabi (Turkey)



18:12 SECONDARY AND PRIMARY CARE SERVICE USE FOR PEOPLE WITH SEVERE MENTAL ILLNESS: EXPLAINING BETWEEN-SITE DIFFERENCES S. Reilly (United Kingdom)

18:20 EFFECT OF PERAMPANEL IN PATIENTS WITH CHRONIC INSOMNIA. E. Suarez (Spain)

18:30 - 18:45

EXHIBITION HALL

Short Break





Innovative research in psychiatry

27.–30.11.2019 CityCube Berlin | Germany

Register now dgppnkongress.de/en









SCIENTIFIC PROGRAMME

MONDAY 8 APRIL 2019





SCIENTIFIC PROGRAMME MONDAY, 8 APRIL 2019

8:00 - 9:30 HALL A

Symposium

The Promise and Challenges of Drug Repurposing in Psychiatry

Chairs: D. Wasserman (Sweden)
I. Bitter (Hungary)

8:00 Boosting Drug Repurposing in Psychiatry Through Machine Learning Approaches

H. So (Hong Kong S.A.R.)

8:20 Can Gene Discovery in Schizophrenia Provide Clues for Repurposing Drugs for Antipsychotic Treatment?

O. Andreassen (Norway)

- 8:40 Repurposing Trials of Minocycline, Methotrexate and Simvastatin in Schizophrenia
 - I. Chaudhry (Pakistan)
- 9:00 Non-Dopaminergic Mechanisms and Negative Symptoms in Schizophrenia: Opportunities for Repurposing?
 - J. Rabinowitz (Israel)
- 9:20 Discussion

8:00 - 9:30 HALL B

Symposium

New Targets to Improve Real-Life Functioning of People with Mental Disorders

Chairs:	P. Gorwood (<i>France</i>)
	H. Kärkkäinen (Finland,

- 8:00 New Targets in the Treatment of Depression and Bipolar Disorder R. McIntyre (*Canada*)
- 8:20 New Targets in the Treatment of Addictions
 W. Van den Brink (*The Netherlands*)
- 8:40 New Targets in the Treatment of Schizophrenia P. Falkai (*Germany*)
- 9:00 New Targets in the Treatment of Eating Disorders
 P. Monteleone (*Italy*)
- 9:20 Discussion



8:00 - 9:30



HALL C

Workshop

Autism in Women: Diagnostic Challenges and Management Strategies

Proposed by the EPA Section on Mental Health and Intellectual Disability (MHID)

Chairs: B. Perera (United Kingdom)
M. Theil (Germany)

- 8:00 High-Functioning Autism in Women
 L. Tebartz Van Elst (Germany)
- 8:13 Camouflage Autism: Diagnostic Challenges in Women with Autism K. Courtenay (United Kingdom)
- 8:26 Autism in Women with Intellectual Disability: Assessment and Management F. Bauer (Germany)
- 8:39 Management Approaches in Women with Autism: Are They Different?
 R. Sheehan (*United Kingdom*)
- 8:52 Increased Risk for Autism Spectrum Disorders (ASD) in Children of Mothers Suffering from Polycystic Ovary Syndrome (PCOS)

 K. Krysta (Poland)
- 9:05 Developing Services for People with Autism: Overcoming Barriers M. Theil (*Germany*)
- 9:18 Discussion

8:00 - 9:30 HALL D

Symposium

Translational Approaches to Study Early Adversity

Chairs: G. Juckel (Germany)
N. Freund (Germany)

- 8:00 Effects of Inflammational Activation in Early States of Schizophrenia G. Juckel (Germany)
- 8:20 Immune Activation via Maternal Milk Leads to Sex-Specific Phenotypes via Identical Developmental Trajectories of Inflammation, Structural Damage and Behavioural Abnormalities I. Weiner (Israel)
- 8:40 Testing a Network Model of ADHD and Inflammation-Related DNA Methylation and the Role of Prenatal Adversities

 E. Barker (United Kingdom)
- 9:00 Epigenetic Mechanisms in a Rodent Model of Early Life Stress
 N. Freund (Germany)
- 9:20 Discussion



8:00 - 9:30 HALL E

Symposium

A Humanitarian Disaster: Mental Health Needs of Forcibly Displaced People in Europe

Chairs: L. Küey (*Turkey*)

M.C. Kastrup (*Denmark*)

8:00 A Humanitarian Disaster: Forcibly Displaced People in Europe

L. Küey (Turkey)

8:20 Displacement Process: Traumas Faced on the Way

I. Graef-Calliess (Germany)

8:40 Mental Health Consequences of Forced Displacement

M. Schouler-Ocak (Germany)

9:00 Mental Health Services for Asylum Seekers and Refugees

M.C. Kastrup (Denmark)

9:20 Discussion

8:00 - 9:30 ECP HALL F

ECP Training Workshop

How to Start and Carry Out a Small Research Study Using Your Own Resources

Chairs: N. Jovanovic (United Kingdom)
R. Softic (Bosnia - Herzegovina)

8:00 How to Do a Small Research Study Using Your Own Resources

N. Sartorius (Switzerland)

8:40 Real Life Examples: Tips and Tricks

D. Krupchanka (Switzerland)

8:00 - 9:30 HALL G

Symposium

Implementing Cognitive Behavioural Therapy as a Standard Method to Treat Insomnia in Psychiatric Practice

Chairs: D. Riemann (Germany)

C. Espie (United Kingdom)

- 8:00 Current Guidelines for the Diagnosis and Treatment of Insomnia
 - D. Riemann (Germany)
- 8:20 Adjusted CBT-i for Sleep Problems in Bipolar and Psychotic Disorders S. Jernelöv (Sweden)
- 8:40 Digital CBT (dCBT) for Insomnia: a Scalable Solution to a Ubiquitous Problem
 - C. Espie (United Kingdom)
- 9:00 Diagnosing and Treating Insomnia in Ambulatory Mental Health Care Services
 - A. Wichniak (Poland)
- 9:20 Discussion



8:00 - 9:30 HALL H

Oral Communications 4

Eating Disorders / Genetics & Molecular Neurobiology / Psychopharmacology and Pharmacoeconomics

Chair: D. Dudek (Poland)

- 8:00 FRACTAL DIMENSIONALITY AS INDEX OF REDUCED CORTICAL COMPLEXITY IN ANOREXIA NERVOSA
 - F. Baggio (Italy)
- 8:11 INTERACTIONS BETWEEN NATURAL PRODUCTS AND PSYCHOTROPIC MEDICATION. "WHAT IS NATURAL DOESN'T HURT" TRUTH OR MYTH?

A.M. Carvalheiro (Portugal)

- 8:22 TRAUMAS IN CHILDHOOD OR ADULTHOOD IN INTERACTION WITH ENDOCANNABINOID GENES LEAD TO DIFFERENT PATHOLOGICAL PHENOTYPE
 - J. Lazary (Hungary)
- 8:33 LEPTIN AND GHRELIN LEVELS IN ALCOHOL DEPENDENT PATIENTS AND THEIR RELATIONSHIP WITH WITHDRAWAL AND CRAVING S. Mehta (India)
- 8:44 DISORDERED EATING IN ADULT INTERNATIONAL ADOPTEES: A POPULATION-BASED COHORT STUDY

M. Strand (Sweden)

8:55 CLINICAL IMPLEMENTATION OF PRE-EMPTIVE PHARMACOGENOMICS IN PSYCHIATRY

E.E. Tsermpini (Greece)

- 9:06 EFFECT OF EXOGENOUS CANNABINOIDS ON EATING BEHAVIOUR
 P. Walecki (Poland)
- 9:17 PSYCHOPHARMACOGENETIC ANALYSIS IN THE STRUCTURE OF A MULTIFACTORIAL PERSONALIZED APPROACH TO THE PATIENT N. Zakharova (Russia)

8:00 - 9:30 HALL I

Oral Communications 5

Depression Part I / Mental Health Care / Classification of Mental Disorders

Chair: M. Wojnar (Poland)

8:00 IMPORTANCE OF COMMUNICATION WITH PATIENTS WITH MENTAL DISORDERS - PRESENTATION OF EDUCATIONAL PROGRAMME A. Wieczorek, Ł (Poland)

8:11 ENHANCING SKILLS NEEDED IN COMMUNICATION WITH PEOPLE WITH MENTAL DISTURBANCES – THE RESULTS OF AN EDUCATIONAL PROGRAMME

A. Fusińska-Korpik (Poland)

8:22 EDUCATIONAL PROGRAMME "CONTACT IN TREATMENT". WHAT WE CAN LEARN FROM IT - QUALITATIVE DATA.

Ł. Cichocki (Poland)

8:33 EVALUATION OF DEPRESSIVE SYMPTOMS BEYOND THE TREATMENT PERIOD IN AN INTEGRATED DATASET FROM BREXANOLONE INJECTION PLACEBO-CONTROLLED TRIALS IN POSTPARTUM DEPRESSION

R. Lasser (USA)

8:44 IMPACT OF MENTAL ILLNESS ON IN-PATIENT HOSPITAL COSTS FOR SOMATIC DISORDERS AND ASSOCIATED FACTORS: A FRENCH NATIONWIDE STUDY

M. Michel (France)

8:55 BIDIRECTIONAL ASSOCIATION BETWEEN BLOOD PRESSURE AND DEPRESSIVE SYMPTOMS IN YOUNG AND MIDDLE AGE ADULTS: A COHORT STUDY

K.S. Oh (Republic of Korea)

9:06 PREDICTING DEPRESSION AND ANXIETY COMPARING MACHINE LEARNING AND DATA MODELLING APPROACHES: A 9-YEAR FOLLOW-UP STUDY

W. Van Eeden (The Netherlands)

9:17 HIGHER PATIENT'S OWN PERCEIVED RATING OF SUPPORT IN FAMILY PRACTICES IN ENGLAND RELATE DIRECTLY TO INCREASED ANTIDEPRESSANT AND ANXIOLYTIC PRESCRIBING. IS THIS CHOOSING WISELY?

A. Heald (United Kingdom)



8:00 - 11:30





HALL J

EPA Course 10

Training for Early Detection and Intervention in Psychosis

Proposed by the EPA Section on Prevention of Mental Disorders

Course Director

A. Riecher-Rössler (Switzerland)

Course Co-Director

N.P. Maric (Serbia)

8:00 - 11:30





HALL K

EPA Course 13

Introduction to Interpersonal Therapy (IPT) and Interpersonal and Social **Rhythm Therapy (IPSRT)**

Proposed by the EPA Section on Psychotherapy

Course Director

B. Lavigne (France)

Course Co-Director

J. Sengelen (Switzerland)

Course Co-Director

O. Omay (Switzerland)

9:30 - 10:00

EXHIBITION HALL

Coffee Break, e-Poster Viewing & Visit the Exhibition

10:00 - 11:30 HALL A

Symposium

Negative Symptoms: New Challenges and Perspectives

Chairs: S. Galderisi (Italy)
A. Raballo (Italy)

- 10:00 Negative Symptoms in Schizophrenia: Evolution of Their Conceptualisation and Relationships with Real-Life Functioning S. Galderisi (Italy)
- Support for the Five Consensus Domains of Negative Symptoms:
 Evidence from Computational Modeling
 G.P. Strauss (USA)
- 10:40 Pharmacological Treatment of Negative Symptoms: New Findings and Perspectives
 - I. Bitter (Hungary)
- 11:00 Genetically Modified Animal Models of Negative Symptoms: Future Challenges for Drug Development
 - C. O'Tuathaigh (Ireland)
- 11:20 Discussion



S 10:00 - 11:30

HALL B

Symposium

Current Developments in Psychiatric Epidemiology: Evidence from Population-Based and Clinical Studies

Proposed by the EPA Section on Epidemiology and Social Psychiatry

Chairs: C. Kuehner (Germany) M. Preisig (Switzerland)

- 10:00 Antecedents and Risk Factors of Mood Disorders in Children of **Affected Parents**
 - M. Preisig (Switzerland)
- 10:20 The Role of Ambulatory Assessment (AA) Phenotypes in Mental Health Research
 - C. Kuehner (Germany)
- 10:40 Psychiatric Epidemiology of Old Age: from Brain Imaging to Society I. Skoog (Sweden)
- 11:00 How Can Employment be Achieved for Patients with Severe Mental Disorder? Translating Efficacy to Effectiveness for the IPS Model A. Mykletun (Norway)
- 11:20 Discussion

Symposium

New Treatment Targets in Addiction Psychiatry: Translating Neuromodulation to the Clinic

Proposed by the EPA Section on Addictive Behaviours

Chairs: F. Kiefer (Germany)

A. Schellekens (The Netherlands)

- 10:00 Transcranial Magnetic Stimulation to Reduce Cognitive Bias in Alcohol Addiction
 - M. Belgers (The Netherlands)
- 10:20 Modification of Substance Intake and Craving Through tDCS in Substance Use Disorder
 - S. Vollstaedt-Klein (Germany)
- 10:40 Using rTMS to Treat Addiction with Co-Morbid Mood DisorderC. Baeken (Belgium)
- 11:00 Deep Brain Stimulation Treatment for Alcohol Use Disorders J. Kuhn (*Germany*)
- 11:20 Discussion



10:00 - 11:30 HALL D

Joint Symposium with EUFAS

Cannabis and the Brain: an Update for Psychiatrists

Chairs: P. Gorwood (France)
G. Dom (Belgium)

- 10:00 Measuring Quantity Matters: the Need for a Standard Joint Unit
 - A. Gual (Spain)
- 10:20 Is it Possible to Measure Brain Disfunction in Cannabis Use Disorders? The Visomotor Rotation Task as a Biomarker of Cerebellum Alterations
 - L. Miquel (Spain)
- 10:40 Heavy Long-Term Cannabis Use: the Neurocognitive Effects J. Cousijn (The Netherlands)
- 11:00 The CANDIS Programme, a Validated Intervention to Treat Cannabis Use Disorders
 - E. Hoch (Germany)
- 11:20 Discussion

10:00 - 11:30 HALL E

Symposium

The Language System in the Major Psychoses: Psychopathological Structure, Neurobiology and Treatment Options

Chairs: T. Kircher (Germany)
W. Strik (Switzerland)

- 10:00 Formal Thought Disorders as a Symptom Dimension of Schizophrenia Linked to Cortico-Basal and Cortico-Cortical Brain Circuits W. Strik (Switzerland)
- Specific Language Disturbances in Major Psychoses: from Syntaxis to Prosody
 P. Brambilla (*Italv*)
- 10:40 Formal Thought Disorders: From Phenomenology to Neurobiology T. Kircher (*Germany*)
- 11:00 Longitudinal Assessment of Brain Structure and Formal Thought Disorders in Schizophrenia
 - B. Crespo-Facorro (Spain)
- 11:20 Discussion



10:00 - 11:30 ECP HALL F

ECP Symposium

Mental Illness and Social Isolation: Why Does it Happen and How Can We Change it?

Chairs: A. Fiorillo (Italy)

N. Sartorius (Switzerland)

- 10:00 Stigma Against People with Severe Mental Illness in Eastern Europe
 - D. Krupchanka (Switzerland)
- 10:20 Peer Support as a Role Model for PatientsS. Gillard (United Kingdom)
- 10:40 Views of Mental Health Professionals on Volunteering in Different European Countries

M. Pinto da Costa (Portugal)

11:00 Social Isolation: Patient and Family Perspectives

H. Kärkkäinen (Finland)

10:00 - 11:30 HALL G

Symposium

Should We Include Exercise in the Regular Treatment of Psychiatric Disorders?

Chairs: F. Rybakowski (*Poland*)
P. Falkai (*Germany*)

- 10:00 The Effects of Continuous Endurance Training on Brain Structure and Function in Multi-Episode Schizophrenia Patients
 - P. Falkai (Germany)
- 10:20 Physical Activity and Cardiorespiratory Fitness in Schizophrenia and the Associations with Mental and Physical Health
 - W. Cahn (The Netherlands)
- 10:40 Randomised Controlled Trial of Physical Activity as an Add-on Intervention in Depressive Adolescent Inpatients: Preliminary Results
 B. Remberk (Poland)
- 11:00 Cerebral Blood Flow During Exercise in Schizophrenia and Depression: fNIRS Study
 - F. Rybakowski (Poland)
- 11:20 Discussion



10:00 - 11:30 HALL H

Oral Communications 6

Child and Adolescent Psychiatry Part II / Migration and Mental Health of Immigrants / Prevention of Mental Disorders / Comorbidity - Dual Pathologies

Chair: M. Janas-Kozik (Poland)

- 10:00 MEDICALLY UNEXPLAINED SYMPTOMS IN CHILDREN: CLINICAL AND SOCIO DEMOGRAPHIC PREDICTORS OF SYMPTOMS IN A SPECIALIST PAEDIATRIC LIAISON SERVICE
 - B. Baig (United Kingdom)
- 10:08 ASYLUM SEEKERS' MENTAL HEALTH. FIRST RESULTS OF THE FINNISH ASYLUM SEEKERS HEALTH AND WELLBEING SURVEY (TERTTU-SURVEY)
 - A. Castaneda (Finland)
- 10:16 THE EVALUATION OF RELATIONSHIP BETWEEN PTSD SYMPTOMS
 AND PSYCHOLOGIC RESILIENCE IN TURKMEN REFUGEES
 MIGRATED INTO TURKEY AFTER IRAQI CIVIL WAR
 - A. Civan Kahve (Turkey)
- 10:24 OFFSPRING OF MOTHERS WITH HYPERTENSIVE DISORDERS OF PREGNANCY ARE AT INCREASED RISK OF ANXIETY DISORDERS: FINDINGS FROM THE ALSPAC STUDY
 - B. Dachew (Australia)
- 10:32 POSSIBLE METABOLIC ALTERATIONS AMONG AUTISTIC MALE CHILDREN: CLINICAL AND BIOCHEMICAL APPROACHES
 - R. Gabra (Egypt)
- 10:40 ALTERATIONS OF RESTING-STATE BRAIN FUNCTION IN PAEDIATRIC BIPOLAR DISORDER PATIENTS WITH AND WITHOUT PSYCHOTIC SYMPTOMS
 - W. Gao (China)
- 10:46 TO THE SEARCH OF CLINICAL AND NEUROANATOMICAL PREDICTORS OF FUNCTIONAL OUTCOME IN INDIVIDUALS AT RISK OF PSYCHOSIS
 - M. Omel chenko (Russia)
- 10:56 QUALITY OF LIFE IN PATIENTS SEEKING TREATMENT FOR ALCOHOL USE DISORDER AND CONCURRENT DISORDERS IN ONTARIO, CANADA
 - A. Samokhvalov (Canada)

11:04 PREVALENCE OF CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS

F. Schultze-Lutter (Germany)

11:12 THE COMORBIDITY OF SCHIZOPHRENIA AND HASHIMOTO'S THYROIDITIS- NEW ASPECTS

P. Sobolevskaia (Russia)

11:20 ANTIPSYCHOTIC PRESCRIBING TRENDS IN A CHILD AND ADOLESCENT POPULATION IN POMERANIA REGION, POLAND 2008–2012

P. Waszak (Poland)

10:00 - 11:30 HALL I

TRIMBOS Workshop

Implementation of Community-Based Mental Health Care in the Recover-E Project

Chairs: I. Petrea (The Netherlands)

J. Samochowiec (Poland)

10:00 The Need for Community-Based Mental Health Care in Central and Eastern Europe: Introduction to the Recover-E Project

I. Petrea (The Netherlands)

10:15 Recover-E in Zagreb

M. Rojnic Kuzman (Croatia)

10:30 The Role of Dutch Specialists from GGZ-NHN in the Recover-E Project R. Keet (*The Netherlands*)

10:45 Plenary Discussion

Ask the Experts 2

Psychiatry and Global Threats

M. Schouler-Ocak (Germany)

Psychiatry Genetics

O. Andreassen (Norway)

How to Manage a WHO Collaborating Centre for Research

D. Wasserman (Sweden)

Functional Recovery in Mood Disorders

R. McIntyre (Canada)

ICD-11: Behind the Scene

W. Gaebel (Germany)

Evidence-Based Mental Health

A. Cipriani (United Kingdom)

Metabolic Monitoring in Psychiatry

M. De Hert (Germany)

11:30 - 11:45

EXHIBITION HALL

Short Break

11:45 - 12:30

HALL A

Plenary Lecture

Preventing Suicide

Chair: W. Gaebel (Germany)

Preventing Suicide

J. Mann (USA)

12:30 - 13:15 EXHIBITION HALL

Lunch Break, e-Poster Presentations & Visit the Exhibition

15:00 - 16:30 HALL A

Debate

Do We Need Compulsory Treatments in Psychiatric Practice?

Chair: M.P. García-Portilla (Spain)

15:00 Pro

T. Kallert (Germany)

15:30 Con

G. Szmukler (United Kingdom)



15:00 - 16:30



HALL B

Workshop

A Quickstart Guide to Set Up a Team in Early Intervention/Detection of Psychosis

Proposed by the EPA Section on Prevention of Mental Disorders

Chairs: M. Rojnic Kuzman (Croatia)

L. Berze (Latvia)

- 15:00 Building a Business Case for an Early Detection Team. What Worked in East London?
 - S. Murguia Asensio (United Kingdom)
- 15:16 Setting Up an Early Detection/Intervention Team in Paris: Resisting and Facilitating Factors

M.O. Krebs (France)

- 15:32 Barriers to Implementing an Early Intervention Programme in Limited Resources Settings and Possible Solutions
 - L. Berze (Latvia)
- 15:48 Leadership Skills Useful to Set Up a New Early Detection Team
 O. Andlauer (United Kingdom)
- 16:04 Recovery for all in the Community: Principles and Key Elements of Community-Based Mental Health Care. The European Community Mental Health Services Network (EuCoMS)
 - R. Keet (The Netherlands)
- 16:20 Discussion

15:00 - 15:45 HALL C

State of the Art

At What Level of Severity Do We Need Antidepressive Drugs?

Chair: C. Hanon (France)

At What Level of Severity Do We Need Antidepressive Drugs?

A. Cipriani (United Kingdom)

15:45 - 16:30 HALL C

State of the Art

Physical Activity and Severe Mental Disorders

Chair: P. Falkai (Germany)

Physical Activity and Severe Mental Disorders

M. De Hert (Germany)



15:00 - 16:30 HALL D

Symposium

In Search of Biomarkers for Mood Disorders

Chairs: J. Rybakowski (Poland)
M. Siwek (Poland)

- 15:00 Immune, Oxidative and Nitrosative Stress Markers in Depression
 P. Gałecki (*Poland*)
- 15:20 Biomarkers of Bipolar Mood Disorder in Relation to Staging of the Illness M. Siwek (*Poland*)
- 15:40 Stem Cell and Pluripotency Markers of Lithium Treatment in Bipolar Mood Disorder
 - J. Rybakowski (Poland)
- 16:00 Biomarkers for Treatment-Resistant Depression Identified in the Whole Genome Sequencing
 A. Serretti (Italy)
- 16:20 Discussion

15:00 - 16:30 HALL E

Symposium

Development and Implementation of Quality Indicators for Mental Health Care in the Danube Region (DAQUMECA)

Chairs: W. Gaebel (Germany)
T. Kurimay (Hungary)

15:00 Development and Implementation of Quality Indicators for Mental

Health Care: Introduction

W. Gaebel (Germany)

15:20 Psychiatry in Transition: Czech MHC Reform

P. Winkler (Czech Republic)

15:40 Raising the Quality of Mental Health Care in Hungary Especially in Light of New Data from DAQUMECA Project

T. Kurimay (Hungary)

16:00 Bulgarian System of Mental Health Services

V. Nakov (Bulgaria)

16:20 Discussion

15:00 - 16:30



HALL F

ECP Training Workshop

Transition from Institutionalised to Community-Based Care: How to Design Psychiatric Facilities?

Chairs: D. Eraslan (*Turkey*)
T.M. Gondek (*Poland*)

15:00 Design of Psychiatric Facilities in the 21st Century

N. Jovanovic (United Kingdom)

15:26 Soteria – Case Study

M. Voss (Germany)

15:52 Soteria - Case Study

J. Danziger (Germany)

16:18 Discussion

94



15:00 - 16:30 HALL G

Symposium

From Clinics to Neurobiology: Bridging the Gap in Bipolar Disorders

Chairs: S. Frangou (USA) G. Sani (Italy)

- 15:00 Lithium Revisited: Investigating Clinical and Neuroimaging Predictors to Lithium
 - A. Young (United Kingdom)
- 15:20 Dopamine Dysregulation in Bipolar Psychosis
 - S. Jauhar (United Kingdom)
- 15:40 Structural Correlates of Illness Progression and Neuroprotection in Bipolar Disorder: a Clinical Perspective
 - A. Simonetti (Italy)
- 16:00 Investigating Heterogeneity in Bipolar Disorder Using Multimodal Imaging S. Frangou (USA)
- 16:20 Discussion

15:00 - 16:30 HALL H

Oral Communications 7

Neuroimaging / Suicidology and Suicide Prevention Part I / Others

Chair: N. Waszkiewicz (Poland)

15:00 PSYCHACHE AND SUICIDE IN PSYCHIATRIC PATIENTS M. Pompili (Italy)

15:10 THE RELEVANCE OF COGNITIVE DEFICIT IN AN ADAPTED ANIMAL MODEL OF IBS IN MICE

R.O. Cojocariu (Romania)

- 15:20 PREDICTORS OF SUICIDE ATTEMPTS IN SELF-HARM ADOLESCENTS: ANALYSIS FROM A CLINICAL AND COMMUNITY SAMPLE T. Duarte (Portugal)
- 15:30 SPECIFIC STRUCTURAL AND FUNCTIONAL UNDERPINNINGS OF PAIN CATASTROPHISING DIMENSIONS IN PATIENTS WITH CHRONIC PAIN: EVIDENCE IN HEADACHE MEDICATION OVERUSE P. Ferentinos (Greece)
- 15:40 CHANGES OF BRAIN FUNCTIONAL CONNECTIVITY AFTER A SINGLE-DOSE OF INTRAVENOUS CITALOPRAM ARE ASSOCIATED WITH ANXIETY TRAIT IN HEALTHY INDIVIDUALS X. Gonda (Hungary)
- 15:50 PERIAQUEDUCTAL GRAY ACTIVATION IN CHRONIC PAIN AND DEPRESSED PATIENTS WITH OFFSET ANALGESIA INDUCTION C.S. Ho (Singapore)
- 16:00 PREVENTION OF SUICIDE BEHAVIOUR IN BELARUS S. Igumnov (Belarus)
- 16:10 A META-ANALYSIS OF TASK-RELATED BRAIN FMRI ACTIVATION IN MAJOR DEPRESSIVE DISORDER, BIPOLAR DISORDER, ANXIETY DISORDER AND POST TRAUMATIC STRESS DISORDER

 D. Janiri (USA)
- 16:20 MINDFUL ACCEPTANCE OR COGNITIVE REAPPRAISAL? LOOKING FOR NEURAL CORRELATES OF EMOTION REGULATION IN MAJOR DEPRESSIVE DISORDER BEFORE AND AFTER MINDFULNESS BASED COGNITIVE THERAPY

M. Kulesza (Poland)



15:00 - 16:30 HALL I

Oral Communications 8

Schizophrenia and Other Psychotic Disorders Part I / Rehabilitation and Psychoeducation

Chair: P. Bieńkowski (Poland)

- 15:00 ANXIOUS ATTACHMENT STYLE AS A MEDIATOR BETWEEN NEGATIVE RELIGIOUS COPING AND DISTRESS LEVELS AMONG OUTPATIENTS WITH FIRST-EPISODE PSYCHOSIS IN SINGAPORE
 - L. Cetty (Singapore)
- 15:08 DECISIONS, PROBABILITIES AND PREDICTIONS: THE
 RELATIONSHIP BETWEEN CHILDHOOD TRAUMA AND COGNITIVE
 AND PERCEPTUAL STRATEGIES ASSOCIATED WITH PSYCHOSIS IN
 A LARGE UK BIRTH COHORT
 - J. Croft (United Kingdom)
- 15:16 GENE CO-EXPRESSION NETWORKS REVEAL PATHWAYS OF CONVERGENCE OF SCHIZOPHRENIA RISK GENES AND OF RESPONSE TO TREATMENT
 - P. Di Carlo (Italy)
- 15:24 THE ROLE OF FACIAL FEAR RECOGNITION AND TRAIT AGGRESSIVENESS IN DETERMINING VIOLENT BEHAVIOUR IN SCHIZOPHRENIA AND IN THE GENERAL POPULATION
 - M. Krakowski (USA)
- 15:32 COGNITIVE FLEXIBILITY, COGNITIVE INHIBITION AND PROBLEM SOLVING IN PATIENTS WITH SCHIZOPHRENIA
 - M. Mak (Poland)
- 15:40 PREGNANCY, DELIVERY AND MOTHERHOOD IN WOMEN WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER: A NATIONAL REGISTER-BASED FOLLOW-UP STUDY FROM FINLAND
 - L. Simoila (Finland)
- 15:48 MOMENT-TO-MOMENT DYNAMICS BETWEEN AUDITORY VERBAL HALLUCINATIONS AND NEGATIVE EFFECT AND THE ROLE OF BELIEFS ABOUT VOICES
 - L.K.H. Chung (Hong Kong S.A.R.)
- 16:04 ENFACEMENT ILLUSION PHENOMENON IN PATIENTS WITH SCHIZOPHRENIA
 - V. Lucarini (Italy)

16:12 CHARACTERISTIC OF STRATEGY IN PHONEMIC AND SEMANTIC FLUENCY IN YOUNG PATIENTS WITH SCHIZOPHRENIA

E. Tyburski (Poland)

16:20 ARE PREMORBID EIGHTH-GRADE SCHOLASTIC ACHIEVEMENTS ASSOCIATED WITH SUBSEQUENT PSYCHIATRIC DISORDERS? A POPULATION-BASED STUDY.

V. Zerem Ullman (Israel)

16:30 - 17:00

EXHIBITION HALL

Coffee Break, e-Poster Presentations & Visit the Exhibition

17:00 - 18:30

HALL A

Symposium

Advancing Partnership in Mental Health Care

Chairs: T. Akiyama (Japan)

N. Sartorius (Switzerland)

17:00 Advancement of Partnerships in Germany

W. Gaebel (Germany)

17:20 Development of Activities of GAMIAN-Europe in Partnership with Different Stakeholders

H. Kärkkäinen (Finland)

17:40 Programmes to Assist Persons with Mental Illness Acquire and/or Retain Jobs Among Stakeholders in Japan

T. Akiyama (Japan)

18:00 Rehabilitation of People with Mental Illness: a Paradigm which Needs re-Examination

N. Sartorius (Switzerland)

Symposium

Diagnosis and Management of Treatment-Resistant Psychiatric Disorders

Proposed by the EPA Section on Psychopharmacology

Chairs: I. Bitter (Hungary)

J. Bobes Garcia (Spain)

17:00 Can a Better Classification of Psychiatric Drugs Reduce Treatment Resistance?

H.J. Möller (Germany)

17:20 Evaluating and Managing Treatment-Resistant Schizophrenia
P. Mohr (Czech Republic)

17:40 Adult ADHD and Substance Use as Comorbid Conditions in Treatment-Resistant Psychiatric Disorders

J.A. Ramos-Quiroga (Spain)

18:00 Progress in the Treatment of Treatment-Resistant Depression S. Kasper (Austria)

17:00 - 18:30 HALL C

Symposium

Anorexia Nervosa: Novel Clinical Features and Biomarkers for Diagnosis

Chairs: P. Gorwood (France)

F. Fernández-Aranda (Spain)

17:00 Specific and Shared Environmental and Biological Risk Factors Associated with Anorexia Nervosa

F. Fernández-Aranda (Spain)

17:20 Excessive Physical Activity in Anorexia Nervosa: an Obsessive Compulsive Trait or an Addictive Behaviour?

P. Gorwood (France)

17:40 Socio-Emotional and Neurocognitive Functioning Predictors of AN and Therapeutic Outcomes

U. Schmidt (United Kingdom)

18:00 Specific Epigenetics Biomarkers of the Physiology and Emotions in AN Patients and Remitters

N. Ramoz (France)



17:00 - 18:30



HALL D

Symposium

Somatic Treatments of Perinatal Mental Disorders in Pregnancy

Proposed by the EPA Section on Women, Gender and Mental Health

Chairs: A. Wieck (United Kingdom)

I. Jones (United Kingdom)

- 17:00 The Reproductive Safety of Psychotropic Drugs: Why Are Data so Difficult to Interpret?
 - I. Jones (United Kingdom)
- 17:20 What Are the Clinical and Legal Issues in Implementing the Ban on Valproate in Pregnancy in Psychiatry?

A. Wieck (United Kingdom)

17:40 The Use of ECT in Childbearing Women

A.L. Sutter-Dellay (France)

18:00 Plasma Levels of Psychotropic Drugs in Pregnancy and Implications for Clinical Practice

N. Bergemann (Germany)

17:00 - 18:30 HALL E

Symposium

Burn-Out Amongst Students and Health Professionals: a Matter of Great Concern

Chairs: C. Hanon (France)

R. J. Van Der Gaag (The Netherlands)

17:00 Burn-Out... An Underestimated Psychopathology

M. Musalek (Austria)

17:20 How Should/Could Professional Associations Act to Promote a Necessary Paradigm Shift to Prevent Burnout in Students, Residents and Health Professionals

S. Bailey (United Kingdom)

17:40 Burnout and Mental Health Problems of Psychiatric Trainees
N. Jovanovic (United Kingdom)

14. Govariovic (Gritted Kirigaciti)

18:00 The Doctor is a Stubborn, Difficult Patient that Might Not Get the Treatment he Needs

R. J. Van Der Gaag (The Netherlands)



17:00 - 18:30

ECP

HALL F

FCP Debate

The Rise in Adolescent Suicide: Can It Be Fixed?

Chairs: O. Kazakova (Belarus)

O. Kilik (Turkey)

Judge: M. Sarchiapone (Italy)

17:00 Con

D. Wasserman (Sweden)

17:45 Pro

J. Sibeoni (France)

17:00 - 18:30



HALL G

Symposium

E-Mental Health Approaches to Prevention and Early Intervention in Affective Disorders

Proposed by the EPA Section on Prevention of Mental Disorders

Chairs: U. Hegerl (Germany)

P. Cuijpers (The Netherlands)

- 17:00 Internet- and Mobile- Based Interventions for the Prevention of Depression
 - D.D. Ebert (Germany)
- 17:25 E-Health Applications for the Self-Monitoring and Self-Management of Depression: Chances and Challenges
 - C. Sander (Germany)
- 17:50 Preventing the Onset of Depressive Disorders: Meta-Analytic Findings

P. Cuijpers (The Netherlands)

18:15 Discussion

17:00 - 18:30 HALL H

Oral Communications 9

Schizophrenia and Other Psychotic Disorders Part III / Ethics and Psychiatry

Chair: P. Bieńkowski (Poland)

17:00 "NEVER SAY DIE" – DYING AS THE FINAL ACT OF LIVING - ROLE OF MODERN MEDICINE AND PALLIATIVE CARE IN CULTURALLY DIVERSE SOCIETIES

A. Budzyna-Dawidowska (New Zealand)

17:10 IS THE CUMULATIVE ENVIRONMENTAL RISK SCORE FOR SCHIZOPHRENIA ASSOCIATED WITH PSYCHOSIS PRONENESS IN THE GENERAL POPULATION?

S. Chanda (The Netherlands)

17:20 THE SEVERITY AND DYNAMICS OF SYMPTOMS ON THE BACKGROUND OF ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA WITH ASSOCIATED METABOLIC SYNDROME V. Dubrovskaya (Russia)

17:30 COULD PATIENTS WITH SCHIZOPHRENIA BE ABLE TO MEASURE THEIR OWN NEGATIVE SYNDROME?

L. Garcia-Alvarez (Spain)

17:40 P3A AND REAL-LIFE FUNCTIONING IN A SAMPLE OF CHRONIC SCHIZOPHRENIA SUBJECTS

G.M. Giordano (Italy)

17:50 MIR-137 AND MIR-34 FAMILY EXPRESSION ABERRATION OF AGE AT ONSET IN SCHIZOPHRENIA PATIENTS WITH NEUROLOGICAL SOFT SIGNS S.H. Lin (Taiwan R.O.C.)

18:00 DIRECT AND INDIRECT COSTS OF AN INTENSIVE FIRST EPISODE OF PSYCHOSIS PROGRAMME (PAFIP), FROM CANTABRIA, SPAIN, DURING THE FIRST YEAR OF INTERVENTION.

J. Mayoral-Van Son (Spain)

18:10 DURATION OF UNTREATED ILLNESS AND DURATION OF UNTREATED PSYCHOSIS AMONGST FIRST TIME PSYCHOSIS - PATIENT COHORT IN CAPITAL CITY OF LATVIA

K. Mieze (Latvia)

18:20 SHORT- AND LONG-TERM CHANGES IN METABOLIC PARAMETERS AND BODY WEIGHT IN CARIPRAZINE-TREATED PATIENTS WITH SCHIZOPHRENIA

B. Sebe (Hungary)



17:00 - 18:30 HALL I

Oral Communications 10

Depression Part II / Old Age Psychiatry / Personality and Personality Disorders

Chair: W.J. Cubała (Poland)

- 17:00 RELATION BETWEEN THE BIG-THREE AND THE HEXACO: BROADER CONCEPTUALISATIONS OF PERFECTIONISM AND ITS **PSYCHOLOGICAL OUTCOMES**
 - A. Araújo (Portugal)
- 17:09 VARIATION IN RECOGNITION OF HAPPY AND SAD FACIAL EXPRESSIONS AND DEPRESSIVE SYMPTOM SEVERITY: A PROSPECTIVE COHORT STUDY
 - J. Bone (United Kingdom)
- 17:18 CHANGES IN SLEEP QUALITY AS A PREDICTOR FOR RESPONSE TO VORTIOXETINE IN MAJOR DEPRESSIVE DISORDER B Cao (China)
- 17:27 ASYMMETRY OF EFFECTIVE CONNECTIVITY DURING RESTING CONDITIONS IN MAJOR DEPRESSIVE DISORDER: ANALYSIS ON HIGH-DENSITY FEG. A. Damborská (Switzerland)
- 17:36 RELATIONSHIP BETWEEN DEPRESSION AND SUICIDAL RISKS IN **ADOLESCENCE**

N. Kornetov (Russia)

- 17:45 SLEEP DEPRIVATION WITH SLEEP PHASE ADVANCE AS AUGMENTATION OF PHARMACOTHERAPY IN TREATMENT-RESISTANT DEPRESSION: BIOCHEMICAL CORRELATES OF RESPONSE
 - E. Kurczewska (Poland)
- 17:54 THE ASSOCIATION BETWEEN AGE-RELATED HEARING LOSS, SPEECH DISCRIMINATION AND LATE-LIFE DEPRESSIVE DISORDERS: RESULTS FROM THE GREATAGE STUDY
 - M. Lozupone (Italy)
- 18:03 BIOLOGICAL RHYTHM DISTURBANCES IN MAJOR DEPRESSIVE DISORDER A.M. Ozcelik (Turkey)
- 18:12 MANAGEMENT OF PEOPLE WITH EMOTIONALLY UNSTABLE, BORDERLINE PERSONALITY DISORDERS (EU-BPD) IN SECONDARY PSYCHIATRIC SERVICES: TIME TO REVISE GUIDELINES AND GET RID OF THE TERM EU-BPD? H. Shahpesandy (United Kingdom)
- 18:21 CRIMINAL ACTS IN NEUROCOGNITIVE DISORDERS
 - T. Talaslahti (Finland)

Ask the Experts 3

Mental Health Disabilities and Respect fo "Will and Preferences"

G. Szmukler (United Kingdom)

Cultural Mobility and Psychiatry Training

M. Pinto da Costa (Portugal)

Anhedonia and Negative Symptoms

G. P. Strauss (USA)

Cannabis and the Brain

J. Cousijn (The Netherlands)

European Psychiatry: from the Editor's Desk

A. Fiorillo (Italy)

Theory of Mind and Mentalisation


K. Koelkebeck (Germany)

Addiction and Related Co-Morbidity

G. Dom (Belgium)

ΤI

η



SCIENTIFIC PROGRAMME

TUESDAY 9 APRIL 2019





SCIENTIFIC PROGRAMME TUESDAY, 9 APRIL 2019

8:00 - 9:30 HALL A

Symposium

Ketamine in Psychiatry: Beyond Depression

Chairs: I. Bitter (Hungary)

M. Musalek (Austria)

8:00 Ketamine for Unipolar and Bipolar Depression

C. Kraus (USA)

8:20 Ketamine for the Treatment of Addiction

B. Marsh (United Kingdom)

8:40 Antidepressant Efficacy and Tolerability of Ketamine and Esketamine

P. Molero (Spain)

8:00 - 9:30 HALL B

Symposium

Psychiatric Malpractice: Twists and Turns Through Regulatory Systems

Chairs: J. Wise (United Kingdom)

R. J. Van Der Gaag (The Netherlands)

- 8:00 The Drama of the German Wings Pilot: Medical Secrecy and Lessons to be Learned
 - F. Montgomery (Germany)
- 8:20 Risk Management: Groupthink, Hindsight-bias, or Misalignment?
 J. Wise (*United Kingdom*)
- 8:40 Why a European Professional Card? A Sad Story of Malpractice in the Netherlands and German Länder: Lessons to be Learned R. J. Van Der Gaag (*The Netherlands*)
- 9:00 Bawa Gaba and Gross Negligence Manslaughter: A Case Of Too Many Good Intentions
 - J. Beezhold (United Kingdom)
- 9:20 Discussion

Workshop

Drug-Drug Interactions in Real Clinical Practice in Elderly Patients with Mental Disorders: How to Avoid?

Proposed by the EPA Section on Old Age Psychiatry and the EPA Section on Psychopharmacology

Chairs: M. Stuhec (Slovenia)

J. Bobes Garcia (Spain)

8:00 A Pharmacokinetic and Pharmacodynamic Overview of Potential and Clinically Important Drug-Drug Interactions

M. Stuhec (Slovenia)

8:16 Important Drug-Drug Interactions of Antidepressants

G. Laux (Germany)

8:32 Important Drug-Drug Interactions of Antipsychotics

J. Bobes Garcia (Spain)

8:48 How to Avoid Inappropriate Drug Treatments and Drug-Drug Interactions in Dementia

G. Stoppe (Switzerland)

9:04 How to Recognise Drug-Drug Interactions with Therapeutic Drug
Monitoring

P. Baumann (Switzerland)

8:00 - 9:30 HALL D

Symposium

Bipolar Disorder: from Prediction to Intervention

Chairs: P. Courtet (France)
B. Etain (France)

8:00 Prediction of Mood Recurrence

B. Etain (France)

8:20 Using Affective Lability to Predict Suicide

E. Olie (France)

8:40 Development of Smartphone Application to Prevent Relapse

D. Hidalgo Mazzei (Spain)

9:00 Smartphones to Improve Suicide Prevention

E. Baca Garcia (Spain)

8:00 - 9:30 HALL E

Joint Workshop GAMIAN-Europe and EPA

Psychiatrists and Patients in Partnership: Obstacles and Solutions

Chairs:	H. Kärkkäinen (Finland)
	S. Galderisi (Italy)

- 8:00 Why GAMIAN-Europe and the EPA Work in Partnership
 - H. Kärkkäinen (Belgium)
- 8:16 Why GAMIAN-Europe and the EPA Work in Partnership S. Galderisi (*Italy*)
- 8:32 The Project on Patient and Clinician Experience: State of the Art M. Muijen (*Belgium*)
- 8:48 My Expectations of a Therapeutic Care Pathway
 A. Drieskens (*Belgium*)
- 9:04 Challenges and Actions to Working Effectively for Patients P. Gorwood (*France*)
- 9:20 Discussion

ECP Training Workshop

How to Publish at the Early Career Stage?

Chairs: K. Koelkebeck (Germany)

A. Schmitt (Germany)

- 8:00 Perspectives from Early Career Psychiatrists
 - S. Jauhar (United Kingdom)
- 8:20 Perspectives from European Psychiatry
 - S. Frangou (USA)
- 8:40 Perspectives from the Women's Archives of Mental Health
 - A. Riecher-Rössler (Switzerland)
- 9:00 Perspectives from the European Archives of Psychiatry and Clinical
 - Neuroscience
 - A. Schmitt (Germany)
- 9:20 Discussion

8:00 - 9:30 HALL G

Symposium

Modern Challenges for Social Psychiatry in a Transition World

Chairs: A. Fiorillo (Italy)

N. Sartorius (Switzerland)

8:00 New Challenges for Psychiatrists

N. Sartorius (Switzerland)

8:20 Integrating Addiction Care into Mental Health Care: from Specialists back to Generalists?

G. Dom (Belgium)

8:40 From Epidemiology to Social Psychiatry: the Impact of New Risk

Factors on the Development of Mental Disorders

K.Y. Ban (United Kingdom)

9:00 Reducing the Mortality Gap in Patients with Severe Mental Disorders

M. Luciano (Italy)

8:00 - 9:30 HALL H

Oral Communications 11

Posttraumatic Stress Disorder / Suicidology and Suicide Prevention Part II / Oncology and Psychiatry

Chair: J. Rymaszewska (Poland)

8:00 WHAT HAPPENS AFTER AN INPATIENT ADMISSION DUE TO SUICIDE ATTEMPT? ANALYSING THE RISK OF RE-ATTEMPTS AND DEATH IN A 10-YEAR FOLLOW-UP STUDY

Á. Fernández-Quintana (Sweden)

8:11 SUICIDE: WHY IN THE ELDERLY?

M.J. Gonçalves (Portugal)

8:22 CLINICAL AND GENETIC FACTORS ASSOCIATED WITH INSOMNIA IN CANCER PATIENTS: A CROSS-SECTIONAL STUDY

A. Hajj (Lebanon)

8:33 INTERACTION BETWEEN COMT POLYMORPHISM AND CHILDHOOD TRAUMA ON SUICIDAL IDEATION IN PATIENTS WITH POST TRAUMATIC STRESS DISORDER

S.H. Lee (Republic of Korea)

8:44 CLINICAL IMPLICATION OF ALTERED INHIBITORY RESPONSE IN POST-TRAUMATIC STRESS DISORDER: ELECTROPHYSIOLOGICAL EVIDENCE FROM A GO/NOGO TASK

S.H. Lee (Republic of Korea)

8:55 COMBINING PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN MDMA-ASSISTED PSYCHOTHERAPY FOR PTSD: PROGRESS IN INTERNATIONAL CLINICAL TRIALS

E. Vermetten (The Netherlands)

9:06 CHILDHOOD AND ADULTHOOD TRAUMATISATION ARE DIFFERENTIALLY ASSOCIATED WITH THE ACTIVITY OF THE RENIN-ANGIOTENSIN-ALDOSTERONE-SYSTEM

J. Terock (Germany)

9:17 PREDICTORS OF ICD-11 ADJUSTMENT DISORDER IN GENERAL POPULATION

P. Zelviene (Lithuania)



8:00 - 11:30

TICKET

HALL I

FPA Course 14

Introduction to Shared Decision-Making Combined with Motivational Interviewing

Course Director

E. Baron (The Netherlands)

Course Co-Director

L. De Backer (Belgium)

8:00 - 11:30



HALL J

EPA Course 15

Borderline Personality Disorder: Treatment with and without Psychotherapy

Course Director

L. Cailhol (Canada)

8:00 - 11:30



HALL K

EPA Course 16

Clinical Descriptions and Diagnostic Guidelines for ICD-11 Mental, Behavioural, and Neurodevelopmental Disorders. How to Understand and Use ICD-11

Course Director

W. Gaebel (Germany)

Course Co-Director

G. Reed (Switzerland)

Course Co-Director

C. Hanon (France)

9:30 - 10:00

EXHIBITION HALL

Coffee Break, e-Poster Viewing & Visit the Exhibition

10:00 - 11:30 HALL A

Symposium

Anti-Inflammatory Treatments: the Next Generation of Antipsychotic Drugs?

Chairs: A. Fiorillo (Italy)

M. Männikkö (Finland)

10:00 From Conventional to Novel Immune Markers Guiding Novel Therapy Development in Psychiatry?

M. Berk (Australia)

10:20 Effect of Antidepressant Treatment on Peripheral Inflammation Markers
 A. Szulc (Poland)

10:40 Understanding Neuroinflammation in Schizophrenia: a Novel Translational Treatment Approach

N. Müller (Germany)

11:00 Targeting Aberrant Inflammatory Pathways in Depression: Opportunities for Domain-Specific Treatments

A. Carvalho (Canada)



10:00 - 11:30 HALL B

Presidential Symposium

Violence and Discrimination in Women with Disabilities

Chairs: S. Galderisi (Italy)
H. Herrman (Australia)

- 10:00 Sexual and Gender-Based Violence in Women and Girls with Disabilities H. Herrman (*Australia*)
- 10:20 Discrimination in Physical/Reproductive/Mental Health in Women with Disabilities

D. Stewart (Canada)

- 10:40 Ethnic Discrimination and Women's Mental Health M. Schouler-Ocak (*Germany*)
- 11:00 GAMIAN-Europe on Behalf of Women with Mental Disabilities
 H. Kärkkäinen (Finland)
- 11:20 Discussion

Workshop

Clinically Important Sexual Dysfunctions for the Psychiatrist

Proposed by the EPA Section on Sexual Medicine and Mental Health

Chairs: M. Waldinger (Belgium)

Z. Zemishlany (Israel)

10:00 Medication, Psychopathology and Sexual Problems: Who is to Blame and Why?

R. Knegtering (The Netherlands)

10:20 Sexual Medicine: the Relevance to Psychiatry

Z. Zemishlany (Israel)

10:40 Common and Rare SSRI Sexual Side Effects

M. Waldinger (Belgium)

11:00 Application of Mathematics on the Ejaculation Time. A New Method in the Genetic Research of Ejaculation Disturbances

P. Janssen (The Netherlands)



10:00 - 11:30 HALL D

Symposium

Innovations in Forensic Psychiatry: 2019

Chairs: J. Heitzman (*Poland*)

B. Völlm (*United Kingdom*)

10:00 Innovations in Treatment of Offenders Diagnosed with Personality Disorders in Forensic Setting

B. Völlm (Germany)

10:20 Innovations in Forensic Psychiatry in Belgium

K. Goethals (Belgium)

10:40 Neurobiology and Pharmacological Management of Compulsive Sexual Behaviour

M. Lew-Starowicz (Poland)

11:00 Variety of Forensic Psychiatry in Europe

P. Gosek (Poland)

Workshop

Psychosis Across Life Span

Proposed by the EPA Section on Old Age Psychiatry

Chairs: A. Schmitt (Germany)

F. Schultze-Lutter (Germany)

- 10:00 Schizophrenia in Late Life: Preliminary Results from the French CSA Study N. Hoertel (France)
- 10:13 A Gap Between Meta-Analyses Results and Real Clinical Practice Psychopharmacology in Older Adults with Schizophrenia Treated with Antipsychotics M. Stuhec (Slovenia)
- 10:26 Long-Term Institutionalisation and Aging Schizophrenia
 P. Lavaud (*France*)
- 10:39 Course of Clinical High Risk (CHR) Criteria in Children and Adolescents F. Schultze-Lutter (*Germany*)
- 10:52 Treatment of Children and Adolescents at Clinical High Risk of Psychosis: a Naturalistic One-year Follow-up Study F. Schultze-Lutter (Germany)
- 11:05 Evaluation of the Smartphone App "Robin" for Supporting the Treatment of Adolescents with Attenuated and Frank Psychotic Symptoms N. Traber-Walker (Switzerland)
- 11:18 Discussion

ECP Training Workshop

Balancing Life, Career, Gender: Insights from Experts

Chairs: P. Trančík (Czech Republic)

E. Sonmez (Turkey)

10:00 Balancing Life, Career, Gender: Do We Ask the Right Questions?

A. Riecher-Rössler (Switzerland)

10:40 Balancing Life, Career, Gender: An Early Career Psychiatrist's Perspective

O. Kazakova (Belarus)

11:20 Discussion

10:00 - 11:30

HALL G

Symposium

Management of Mood Disorders: Current Treatments and the Potential of GABA-A Receptor Positive Allosteric Modulators in Postpartum Depression and Major Depressive Disorder

Chairs: S. Frangou (USA)

G. Apter (France)

10:00 An Overview of Depression: Disease Burden and Treatment History

S. Frangou (USA)

10:20 Postpartum Depression Epidemiology and Diagnosis

G. Apter (France)

10:40 GABAergic Mode of Action and GABA-A Receptor Positive Allosteric Modulators in Postpartum Depression

S.M. Park (Switzerland)

11:00 GABAergic Mode of Action and GABA-A Receptor Positive Allosteric Modulators in Major Depressive Disorder

R. Lasser (USA)

10:00 - 11:30 HALL H

Oral Communications 12

Schizophrenia and Other Psychotic Disorders Part II / Mental Health Policies

Chair: M. Jarema (Poland)

10:00 VIOLENCE AGAINST PSYCHIATRY TRAINEES IN EUROPEAN REGION COUNTRIES: AN OVERVIEW

G. Erzin (Turkey)

10:12 NEUROMETABOLIC CORRELATES OF COGNITIVE PROCESSING SPEED IN PATIENTS WITH SCHIZOPHRENIA AND THEIR HEALTHY SIBLINGS – A 1H MRS SPECTROSCOPY APPLICATION

M. Futyma- Jędrzejewska (Poland)

10:24 CLINICAL AND GENETIC FACTORS ASSOCIATED WITH RESISTANCE TO TREATMENT IN PATIENTS WITH SCHIZOPHRENIA: A CASE-CONTROL STUDY

A. Hajj (Lebanon)

10:36 REMISSION AND RECOVERY IN FIRST-EPISODE PSYCHOSIS: THE COIMBRA EARLY PSYCHOSIS UNIT

S. Magano (Portugal)

10:48 ATTACHMENT STYLES AND THEORY OF MIND ABILITIES NON-PSYCHOTIC ADULT OFFSPRING OF PATIENTS WITH SCHIZOPHRENIA

C. Sahbaz (Turkey)

11:00 FIRST PSYCHOTIC EPISODE IN FEMALE TAKING DIETARY SUPPLEMENT COCKTAIL

A.F. Teixeira (Portugal)

11:12 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY HAS REVEALED SERUM ALBUMIN CONFORMATIONAL DISTURBANCES IN PATIENTS WITH FIRST EPISODE OF SCHIZOPHRENIA

M. Uzbekov (Russia)

11:30 - 11:45

EXHIBITION HALL

Short Break



11:45 - 12:30 HALL A

Plenary Lecture

The Dialogue Between Genetic and Environmental Risk Factors in Mood and Anxiety Disorders

Chair: P. Gorwood (France)

The Dialogue Between Genetic and Environmental Risk Factors in Mood and Anxiety Disorders

E. Binder (Germany)

12:30 - 13:15 EXHIBITION HALL

Lunch Break, e-Poster Presentations & Visit the Exhibition

13:15 - 14:45 HALL A

Joint Symposium with the EBC

Parkinson's Disease and Psychiatry

Chairs: M. Di Luca (Italy)

P. Gorwood (France)

P. Boyer (France)

- 13:15 Neuropsychiatric Symptoms in Prodromal and Early Parkinson's Disease F. Geibl (Germany)
- 13:37 Depression: Risk Factor or Early Symptom in Parkinson Disease?

A. Leentjens (The Netherlands)

Workshop

Suicide Prevention and Assisted Suicide in the Elderly

Proposed by the EPA Section on Old Age Psychiatry and the EPA Section on Suicidology and Suicide Prevention

Chairs: G. Stoppe (Switzerland)
G. Dom (Belgium)

- 13:15 Suicide and Assisted Suicide in an Ageing Society: the Ethical View P. Zeppegno (Italy)
- 13:35 The Frail Elderly and the Wish to Die F. Riese (Switzerland)
- 13:55 European Alliance against Depression: Interventions Targeting Depression and Suicidal Behaviour in Old Age
 U. Hegerl (Germany)
- 14:15 Swiss Physicians and Assisted Suicide: New Guidelines Under Debate G. Stoppe (Switzerland)
- 14:35 Discussion



13:15 - 14:00 HALL C

State of the Art

Long-Term Schizophrenia Medication: Targeting Minimal Effective Dose, Treating Intermittently, or Choosing the 'Safe Side'?

Chair: T. Kurimay (Hungary)

Long-Term Schizophrenia Medication: Targeting Minimal Effective Dose, Treating Intermittently, or Choosing the 'Safe Side'?

S. Leucht (Germany)

14:00 - 14:45 HALL C

State of the Art

Lithium: 70 Years of Treatment in Psychiatry

Chair: J. Samochowiec (Poland)

Lithium: 70 Years of Treatment in Psychiatry

J. Rybakowski (Poland)

13:15 - 14:45 HALL D

Symposium

E-Mental Health: the Digital Revolution in Mental Health Care

Chairs: W. Gaebel (*Germany*)
O. Vlijter (*The Netherlands*)

13:15 The eMEN Interreg Project: Introduction and First Results

O. Vlijter (The Netherlands)

13:35 Implementation Approaches and Challenges of E-Mental Health

H. Riper (The Netherlands)

13:55 E-Mental Health: Experiences from Ireland

K. Cullen (Ireland)

14:15 eMEN: Focus on Transnational Policy Solutions

W. Gaebel (Germany)

14:35 Discussion

Symposium

Personalised Psychiatry: Novel Neuroimaging Tools for Clinical Translation

Proposed by the EPA Section on Neuroimaging

Chairs: S. Frangou (USA)
L. A. Antonucci (Italy)

- 13:15 Predicting Functional Disability in Young Adults at Risk for Psychosis and Relapsing Depression Using Multi-Site, Multi-Modal Machine Learning: Results from the European Pronia Project L. A. Antonucci (*Italy*)
- 13:35 Clinical Implications for Big Data Approaches to Mental Health Research
 T. Kaufmann (Norway)
- 13:55 Parsing Heterogeneity in Healthy Individuals and Patients with Psychosis: Clinical Implications
 - S. Frangou (USA)
- 14:15 Gyrification-Based Connectomes for the Implementation of Structural MRI Into Clinical Routine
 - S. Borgwardt (Switzerland)
- 14:35 Discussion

13:15 - 14:45 HALL F

Symposium

Effective Prevention and Assessment of Risk of Suicidal Behaviour in Different Populations with Special Focus on Young People

Chairs: D. Wasserman (Sweden)
M. Wojnar (Poland)

- 13:15 Universal Suicide Prevention in Schools
 - D. Wasserman (Sweden)
- 13:35 Suicide in Hungary: Special Focus on Adolescent Suicide
 J. Balazs (*Hungary*)
- 13:55 Verbal Suicide Scale (VSS). Measuring Attitudes Toward Suicide: New Diagnostic Approach
 - A. Szulc (Poland)
- 14:15 Suicidal Behaviour Related to Psychoactive Substance Use: Genetic and Clinical Risk Factors
 S. Fudalej (*Poland*)
- 14:35 Discussion

Symposium

Female Gender, Reproductive Events and the Expression of Selected Mental Disorders

Proposed by the EPA Section on Women, Gender and Mental Health and the EPA Section on Neurodevelopmental Disorders Across the Lifespan (NDAL)

Chairs: A. Wieck (United Kingdom)

J.A. Ramos-Quiroga (Spain)

- 13:15 What do We Know about How Childbearing Impacts Mood Disorders?

 I. Jones (United Kingdom)
- 13:35 Menopause and Mental Health
 A. Riecher-Rössler (Switzerland)
- 13:55 Mood Changes Related to Reproductive Events in Women with ADHD S. Kooij (*The Netherlands*)
- 14:15 The Role of Emotional Dysregulation in Women with ADHD and Borderline Personality Disorder: a Comparative Analysis
 P. Asherson (United Kingdom)
- 14:35 Discussion

13:15 - 14:45 HALL I

Symposium

Problematic Use of the Internet: What the Psychiatrist Needs to Know

Chair: B. Dell'Osso (Italy)

- 13:15 Conceptualisation of PUI: Between Compulsivity, Impulsivity and Addiction Z. Demetrovics (*Hungary*)
- 13:35 Exploring PUI's Determinants, Assessment and Clinical Course K. Ioannidis (*United Kingdom*)
- 13:55 Diagnosis and Conceptualisation of Gaming Disorder J. Billieux (*Luxembourg*)
- 14:15 Introducing a COST Action on PUI: Aims, Network and Activities Results
 B. Dell'Osso (Italy)
- 14:35 Discussion



13:15 - 14:45 HALL J

Oral Communications 13

Child and Adolescent Psychiatry Part I / Philosophy and Psychiatry / Cultural Psychiatry / Quality Management

Chair: B. Remberk (Poland)

- 13:15 VITAMINE DEFICIENCY IN CHILD AND ADOLESCENT PSYCHIATRIC INPATIENTS: A 3-YEAR RETROSPECTIVE STUDY. A COMPREHENSIVE ANTHROPOMETRIC AND DIAGNOSTIC ANALYSIS.
 - G. Anmella Diaz (Spain)
- 13:25 ANALYSIS OF THE EUROPEAN COMMISSION'S MENTAL HEALTH RESEARCH PROJECTS FUNDING
 - J.B. Hazo (France)
- 13:35 COPING AND ACCULTURATION IN SPANISH AND MEXICAN IMMIGRANTS IN POLAND
 - Z. Lebiecka (Poland)
- 13:45 EFFECT OF CARDIO-METABOLIC MONITORING ON HBA1C LEVELS IN PATIENTS ON ANTIPSYCHOTICS IN AN OUTPATIENT CLINIC P. Manocha (USA)
- 13:55 OUTCOMES OF NARRATIVE THERAPY WITH INDIGENOUS PEOPLE WHO HAVE ATTEMPTED SUICIDE
 - L. Mehl-Madrona (USA)
- 14:05 WHAT DO WE KNOW ABOUT MINORS WHO ATTEND THE CHILD AND ADOLESCENT MENTAL HEALTH OUTPATIENT UNIT? CONCLUSIONS AFTER A TWO-YEAR FOLLOW-UP
 - A. Novo-Ponte (Spain)
- 14:15 THE EFFECT OF SOCIAL STIGMATISATION FEAR AND SELF-STIGMATISATION ON PSYCHOLOGICAL HELP-SEEKING IN HIGH SCHOOL STUDENTS
 F. Oflaz (Turkey)
- 14:25 EXPLORING ASSOCIATIONS BETWEEN "BODY SIZE PERCEPTION, DISORDERED EATING, BMI AND MENTAL DISTRESS" AND "DIETING" IN A NORWEGIAN COMMUNITY ADOLESCENT SAMPLE, THE NORD-TRØNDELAG HEALTH STUDY (YH3)
 - F. Saeedzadeh Sardahaee (Norway)
- 14:35 THE 'SUICIDALITY: TREATMENT OCCURRING IN PAEDIATRICS' (STOP)
 PROJECT: A COMPREHENSIVE WEB-BASED METHOD FOR THE ASSESSMENT
 AND MONITORING OF SUICIDALITY IN CHILDREN AND ADOLESCENTS
 - P. Santosh (United Kingdom)

13:15 - 14:45 HALL K

Oral Communications 14

Forensic Psychiatry / Sexual Medicine and Mental Health / Substance Related and Addictive Disorders

Chair: K. Goethals (Belgium)

- 13:15 THE FORENSIC RESEARCH AND TECHNOLOGY STUDY: FORETECH STUDY Y. Bouman (*The Netherlands*)
- 13:27 SEXUAL THERAPY IN THE MANAGEMENT OF PREMATURE EJACULATION: WHEN AND FOR WHOM? PRACTICE PATTERNS AND ATTITUDES FOR SEXUAL THERAPY IN TURKISH UROLOGISTS N.G. Usta Saglam (*Turkey*)
- 13:39 SEXUALITY IN SCHIZOPHRENIA: A 20-YEAR SYSTEMATIC REVIEW F. Almeida (Portugal)
- 13:51 ASSOCIATION BETWEEN PROBLEM GAMBLING, PROBLEM GAMING AND PROBLEMATIC INTERNET USE GENERAL POPULATION DATA FROM SEVEN EUROPEAN COUNTRIES N. Broman (Sweden)
- 14:03 EFFECT OF ADOLESCENTS' DEPRESSION ON INTERNET GAMING DISORDER: RESULT OF ONE-YEAR FOLLOW-UP
 S.J. Jo (Republic of Korea)
- 14:15 BENZODIAZEPINE USE AMONG PATIENTS IN A BUPRENORPHINE TREATMENT FOR OPIOID DEPENDENCE: FINDINGS OF A CROSS-SECTIONAL STUDY
 - C. Oliveira (Portugal)
- 14:27 RELAPSING RISK FACTORS IN POLIADDICTIONS: IS ALSO ABOUT POSITIVE EMOTIONS
 - R. Santos (Portugal)



INDEX OF AUTHORS

INDEX OF AUTHORS





			00.444
A		Bobes Garcia, J.	99, 111
Adamis, D.	66	Bone, J.	105
Aichberger, M.	42	Borgwardt, S.	129
Akiyama, T.	98	Bostwick, J.M.	40
Almeida, F.	134	Bouckaert, F.	35 134
Andlauer, O.	91	Bouman, Y.	125
Andreassen, O.	71, 89	Boyer, P.	
Anmella Diaz, G.	133	Brambilla, P.	35, 84
Antonucci, L. A.	129	Brewin, C.	47 134
Apter, G.	123	Broman, N.	
Arango, C.	47	Budzyna-Dawidowska, A.	104
Araújo, A.	105	C	
Arnaoutoglou, N.	46	Cabaços, C.	54
Asherson, P.	27, 131	Cahn, W.	86
В		Cailhol, L.	117
Baca Garcia, E.	112	Calvet, B.	35
Baeken, C.	82	Cao, B.	105
Baggio, F.	77	Carvalheiro, A.M.	77
Baig, B.	87	Carvalho, A.	118
Bailey, S.	102	Castaneda, A.	87
Balazs, J.	58, 130	Cella, M.	41
Ban, K.Y.	37, 115	Cetty, L.	97
Baradits, M.	54	Chanda, S.	104
Barker, E.	74	Chan, E.	56
Baron, E.	117	Chaudhry, I.	71
Batalla, A.	60	Chisholm, D.	26
Bauer, F.	73	Chrobok, A.	54
Baumann, P.	111	Chung, L.K.H.	97
Beezhold, J.	45, 53, 65, 110	Cipriani, A.	89, 92
Belgers, M.	82	Cirulli, F.	39
Bergemann, N.	101	Civan Kahve, A.	87
Berk, M.	118	Cohen, D.	40
Berrisford, G.	38	Cojocariu, R.O.	96
Berze, L.	91	Correll, C.U.	64
Bhugra, D.	34, 42, 57, 61	Courtenay, K.	73
Bieber, E.	40, 57	Courtet, P.	112
Bieńkowski, P.	97, 104	Cousijn, J.	83, 106
Billieux, J.	132	Crespo-Facorro, B.	84
Binder, E.	125	Croft, J.	97
Bitter, I.	71, 80, 99, 109	Cubała, W.J.	105
Bloch, Y.	54	Cuijpers, P.	103

Cullen, K.	128	3	, 50, 95, 114, 123, 129
D		Freund, N.	74
Dachew, B.	87	Fudalej, S.	130
Damborská, A.	105	Fusińska-Korpik, A.	78
Danziger, J.	94	Futyma-, M.	124
Dawson, G.	47	G	
De Backer, L.	117	Gabra, R.	87
De Hert, M.	89, 92	Gaebel, W.	26, 36, 45, 53, 61,
Delic, M.	45	daebei, w.	89, 94, 98, 117, 128
Dell'Osso, B.	132	Galderisi, S.	25, 36, 41, 47, 53,
Demetrovics, Z		,	63, 80, 113, 119
Deuschle, M.	. 132	Gałecki, P.	57, 93
Di Carlo, P.	97	Gao, Q.	66
Di Luca, M.	125	Gao, W.	87
Di Luca, M. Dinan, T.	33	Garcia-Alvarez, L.	104
Dollfus, S.	51	García-Portilla, M.P.	. 90
Dom, G.	50, 60, 83, 106, 115, 126	Garety, P.	41, 47
Drieskens, A.	113	Gargot, T.	46
Duarte, T.	96	Geibl, F.	125
•		Gillard, S.	85
Dubrovskaya, V	. 104	Giordano, G.M.	104
Dudek, D.	//	Goethals, K.	121, 134
E		Gonçalves, M.J.	116
Еар, С.В.	64	Gonda, X.	52, 96
Ebert, D.D.	103	Gondek, T.M.	37, 46, 94
El-Higaya, E.	37	Gorwood, P.	25, 47-48, 63,
Eraslan, D.	94		72, 83, 100, 113, 125
Eriksson, E.	38	Gosek, P.	56, 121
Erzin, G.	124	Grabowski, J.	66
Espie, C.	76	Graef-Calliess, I.	75
Etain, B.	52, 112	Gramaglia, C.	42
_		Gual, A.	83
F		Gureje, O.	48
Falkai, P.	33, 57, 63, 72, 86, 92	Gurrera, R.	66
Fañanás, L.	39	Gustaw-Rothenber	g, K. 66
Farooq, S.	40, 57	1.1	
Ferentinos, P.	96	H	446 404
Fernández-Arar	·	Hajj, A.	116, 124
Filip, M.	46		6, 53, 61, 92, 102, 117
Fiorillo, A.	28, 61, 85, 106, 115, 118	Haro, J.M.	25
Fountoulakis, K		Hazo, J.B.	133
Frančišković, T.	62	Heald, A.	78



Hegerl, U.	103, 126	Kellner, C.	28
Heitzman, J.	56, 121	Kiefer, F.	82
Hermans, M.	61	Kilik, O.	103
Herrman, H.	26, 119	Killaspy, H.	53
Heun, R.	28, 35	Kircher, T.	84
Hidalgo Mazzei, D.	112	Kjær, J.N.	37, 46
Hiemke, C.	29	Knegtering, R.	120
Hoch, E.	83	Koelkebeck, K.	53, 106, 114
Ho, C.S.	96	Kooij, S.	27, 131
Hoertel, N.	122	Kornetov, N.	105
Hofer, A.	51	Koutsouleris, N.	50
Hogan, S.	25	Koychev, I.	28
I		Krabbendam, L.	50
	0.6	Krakowski, M.	97
Igumnov, S.	96	Kraus, C.	109
Ioannidis, K.	132	Krebs, M.O.	91
J		Krukow, P.	54
Jae, Y.M.	56	Krupchanka, D.	75, 85
Jakubczyk, A.	60	Krysta, K.	73
Janas-Kozik, M.	87	Kucharska, K.	44
Janiri, D.	96	Kuehner, C.	81
Janssen, P.	120	Küey, L.	34, 75
Jarema, M.	124	Kuhn, J.	82
Jauhar, S.	95, 114	Kulesza, M.	96
Javed, A.	48	Kurczewska, E.	105
Jernelöv, S.	76	Kurimay, T.	34, 94, 127
Jones, E.	34		
Jones, I.	27, 101, 131	Lasser, R.	78, 123
Jo, S.J.	134	Laux, G.	29, 111
Jovanovic, N.	75, 94, 102	Lavaud, P.	122
Juckel, G.	74	Lavigne, B.	79
К		Lazary, J.	77
Kahl, K.	64	Lebiecka, Z.	133
Kallert, T.	90	Lee, H.	66
Karakula-Juchnowic		Leentjens, A.	125
Kärkkäinen, H.	72, 85, 98, 113, 119	Lee, S.H.	116
Kasper, S.	72, 63, 96, 113, 119	Le Roch, K.	54
Kastrup, M.C.	75	Leucht, S.	127
Kaufmann, T.	129	Lew-Starowicz, M.	121
Kazakova, O.	61, 103, 123	Liester, M.	56
Keet, R.	88, 91	Lin, S.H.	104
- •	,		

Lozupone, M.	105	Murawiec, S.	54
Lucarini, V.	97	Murguia Asensio, S.	91
Luciano, M.	115	Musalek, M.	102, 109
M		Mykletun, A.	81
Maciukiewicz, M.	64	N	
Magano, S.	124	Nabi, A.	66
Maj, M.	45	Naesström, M.	54
Mak, M.	97	Nakamura, A.	59
Männikkö, M.	118	Nakov, V.	94
Mann, J.	89	Nomidou, A.	26
Manocha, P.	133	Nordentoft, M.	36, 41
Maras, A.	66	Novo-Ponte, A.	133
Maric, N.P.	79		
Marsh, B.	109	0	
Martin Carrasco, M.	65	Oflaz, F.	133
Mayoral-Van Son, J.	104	Oh, K.S.	78
McDonald, E.	38	Okai, D.	28
McIntyre, R.	72, 89	Olie, E.	112
McLoughlin, D.	28	Oliveira, C.	134
Mehl-Madrona, L.	133	Omay, O.	79
Mehlum, L.	58	Omel, M.	87
Mehta, S.	77	Orosa Duarte, A.	56
Melchior, M.	59	O'Tuathaigh, C.	80
Mesbah, R.	56	Ozcelik, A.M.	105
Meyer, B.	56	Р	
Meyer-Lindenberg, A.	47	Palma-Gudiel, H.	39
Michel, M.	78	Park, S.M.	123
Mieze, K.	104	Perera, B.	73
Miquel, L.	83	Petrea, I.	25, 88
Misiak, B.	34	Pinto, M.	62, 85, 106
Mohr, P.	99	Plaza Estrade, A.	52
Molero, P.	109	Plummer, C.	61
Möller, H.J.	99	Pompili, M.	52, 96
Monteleone, A.	44	Popovic, M.	25
Monteleone, P.	44, 72	Potenza, M.	36
Montgomery, F.	110	Preisig, M.	81
Moorey, S.	27, 46	Provenzi, L.	39
Mucci, A.	29, 51	Psouni, E.	59
Muijen, M.	113	Puras, D.	26
Müller, N.	118		
Muñoz, E.	56	Q	



Quattrone, D.	45	Sengelen, J.	79
R		Seregin, A.	56
Raballo, A.	62, 80	Serretti, A.	93
Raballo, A. Rabinowitz, J.	71	Sethna, V.	59
Ramos-Quiroga, J.A.		Shahpesandy, H.	105
Ramoz, N.	100	Sheehan, R.	73
·	43	Sibeoni, J.	103
Ratajczak, M.		Sienaert, P.	28
Reed, G.	45, 117	Simoila, L.	97
Reilly, S.	67	Simonetti, A.	95
Remberk, B.	86, 133	Siwek, M.	93
Riecher-Rössler, A.	36, 49, 58, 79, 114, 123, 131	Skoog, I.	81
Riemann, D.	76	Sobanski, E.	27, 57
Riese, F.	126	Sobolevskaia, P.	88
Rihmer, Z.	52	So, C.	62
Riper, H.	128	Softic, R.	75
Robert, G.	35	So, H.	71
Rojnic Kuzman, M.	88, 91	Sonmez, E.	123
Rybakowski, F.	86	Sorel, E.	48
Rybakowski, J.	51, 93, 127	Stanghellini, G.	53
Rymaszewska, J.	116	Stewart, D.	119
Rymaszewska, J.	110	Stoppe, G.	111, 126
S		Strand, M.	77
Saeedzadeh Sardaha	ee, F. 133	Strauss, G. P.	106
Sahbaz, C.	124	Strauss, G.P.	80
Saiz Garcia, H.	46	Strik, W.	84
Samochowiec, J.	33, 43, 63, 88, 127	Stubbs, B.	33
Samokhvalov, A.	87	Stuhec, M.	111, 122
Sampogna, G.	45, 61	Suarez, E.	67
Sander, C.	103	Sutter-Dellay, A.L.	49, 101
Sani, G.	95	Szmukler, G.	90, 106
Santosh, P.	133	Szulc, A.	43, 57, 63, 118, 130
Santos, R.	134	_	
Sarchiapone, M.	42, 103	T	
Sartorius, N. 39, 55	5, 65, 75, 85, 98, 115	Talarowska, M.	66
Schellekens, A.	60, 82	Talaslahti, T.	105
Schmidt, U.	100	Tebartz Van Elst, L.	73
Schmitt, A.	114, 122	Teixeira, A.F.	124
Schouler-Ocak, M.	34, 42, 75, 89, 119	Terock, J.	116
Schultze-Lutter, F.	58, 88, 122	Theil, M.	73
Sebe, B.	104	Thibaut, F.	36, 49
Semenova, N.	38	Tosato, S.	36
-,			

Tournikioti, K.	57	W	
Traber-Walker, N.	122	Walecki, P.	77
Trančík, P.	37, 62, 123	Walker, M.	26
Treasure, J.	44	Wasserman, D.	26, 39, 55, 71,
Tsermpini, E.E.	77	·	89, 103, 130
Tyburski, E.	98	Waszak, P.	88
Tyszkiewicz-Nwafor, M.	44	Waszkiewicz, N.	45, 96
U		Weiner, I.	74
	174	Weinstein, A.	36
Usta Saglam, N.G.	134	Wichniak, A.	76
Uzbekov, M.	124	Wieck, A.	27, 38, 101, 131
\bigvee		Wieczorek, A.	78
Van Der Gaag, R. J.	55, 65, 102, 110	Wigman, J.	36
Van Eeden, W.	78	Winkler, P.	94
Van der Waerden, J.	59	Wise, J.	110
Van Os, J.	45, 58	Wojnar, M.	60, 78, 130
Van, W.	45, 72	Y	
Vavrusova, L.	38, 55	Young, A.	95
Veling, W.	41	roung, A.	93
Ventura, J.	29	Z	
Vermetten, E.	116	Zakharova, N.	77
Vlijter, O.	128	Zakotnik, J. M.	53
Völlm, B.	121	Zalsman, G.	48, 58
Vollstaedt-Klein, S.	82	Zandersen, M.	37
Volpe, U.	35, 62	Zannas, A.	39
Voss, M.	94	Zelviene, P.	116
Waldinger, M.	120W	Zemishlany, Z.	120
		Zeppegno, P.	126
		Zerem Ullman, V.	98
		Zohar, J.	57, 62



COMPANY & EXHIBITION GUIDE



Deep Transcranial Magnetic Stimulation (TMS) represents a new era in the treatment of MDD, OCD, PTSD and more. BrainsWay's non-invasive, well-tolerated outpatient treatment has been proven in clinical studies to mitigate the many symptoms of common brain disorders.

BrainsWay Multicenter Trials:

MDD

5 weeks - active response / remission rates: 38.4% / 32.6% 16 weeks - active response / remission rates: 72.7% / 63.6%*



OCD

6 weeks - active response / partial response rates: 38.1% / 54.76% 4 weeks follow up - active response / partial response: 45.24% / 59.52%



* Response - Reduction of at least 30% in VROCS score from baseline Partial response rate comparison at the 6 week visit, where response is defined as a reduction of at least 20% in YBOCS score from baseline

Visit us: Booth #12 at EPA 2019

and experience stimulation of your motor cortex

To schedule a hands-on demonstration: contact@brainsway-global.com



ACKNOWLEDGEMENTS

The EPA wishes to express its gratitude for the contribution and support of the following healthcare industries:

PLATINUM SPONSORS



GOLD SPONSORS







SILVER SPONSORS







BRONZE SPONSORS







EXHIBITORS











































EXHIBITORS



































INDUSTRY SUPPORTED SATELLITE SYMPOSIA

SUNDAY, 7 APRIL, 2019

13:15-14:45 | Hall: E



The Burden of Schizophrenia across age and gender

Chair: Sofia Brissos, Lisbon 13:15 Gender differences in schizophrenia symptoms Anita Riecher-Rössler, Switzerland 13:45 Pharmacological treatment selection: age and gender differences David Taylor, UK 14:15 The economic burden of schizophrenia across gender and age groups Andrea Fagiolini, Italy

13:15-14:45 | Hall: C

Timely decision making in major depressive disorder (MDD): novel strategies



Chair:	Dominika Dudek, Poland
Scientific	Committee: Eduard Vieta, Spain; Andrea Fagiolini, Italy
13:15	Welcome and introduction Dominika Dudek, Poland
13:25	Refining dimensions and dynamics of MDD in clinical practice Andrea Fagiolini, Italy
13:50	Sequential strategies: the way forward Mazda Adli, Germany
14:10	Decision making: what matters for patients Wiesław Jerzy Cubała, Poland
14:30	Panel discussion with all speakers (general Q&A session) Dominika Dudek, Poland; Mazda Adli, Germany and Wiesław Jerzy Cubała, Poland
14:40	Closing remarks Dominika Dudek, Poland



13:15-14:45 | Hall: D

Can we still improve patient functioning in schizophrenia?





13:15	Chairman's introduction István Bitter, Hungary
13:20	Improving negative symptoms and patient functioning state of the art Stefan Leucht, Germany
13:40	Mechanism of action of cariprazine: molecular and behavioural effects related to negative symptoms Giorgio Racagni, Italy
14:00	Clinical studies and real-life experience: challenges and cases Peter Falkai, Germany
14:20	Closing and Discussion István Bitter, Hungary

12:30-13:10 | Exhibition Hall

Training session on deprexis®, an online CBT program



Björn Meyer (GAIA AG), Germany

MONDAY, 8 APRIL 2019

13:15-14:45 | Hall: C

How to optimise the daily care of patients with schizophrenia: from data to practice



Scientific Committee: José M. Olivares, Spain; Christoph U. Correll, Germany/USA

Chair: José M. Olivares, Spain

Co-chair: Jerzy Samochowiec, Poland

- 13:15 **Welcome and introduction** José Manuel Olivares, Spain
- 13:25 Living with schizophrenia: the experience of the patient
 A person living with schizophrenia from Spolek KOLUMBUS, Czech
 Republic, who is also a Board member of GAMIAN-Europe; and José
 Manuel Olivares, Spain
- 13:40 Long-acting treatments in schizophrenia: WHEN and for WHOM? Pierre-Michel Llorca, France
- 14:00 Long-acting treatments in schizophrenia: a call to action Christoph Correll, Germany, USA
- 14:20 Panel discussion with all speakers (general Q&A session)
 José Manuel Olivares, Spain and Jerzy Samochowiec, Poland
- 14:40 Closing remarks
 José Manuel Olivares, Spain

12:30-13:10 | Exhibition Hall

T. Kanellopoulos, Greece



Feedback on deprexis® from clinical practice experience

R. Psaras, Greece



13:15-14:45 | Hall: B




Missed or misdiagnoses: could it be ADHD?

- 13:15 Chairman's welcome David Bull, UK
- **13:20** Scene-set: ADHD in general adult psychiatry Susan Young, UK
- 13:35 ADHD and comorbidities: differential diagnosis:
 - Depression and Anxiety Larry Klassen, Canada
 - **Bipolar Disorder** Peter Mason, UK
 - Borderline Personality Disorder Alexandra Philipsen, Germany
 - Substance Use Disorder Antoni Ramos, Spain

Panel discussion forum

- **14:05** Voice of the patient; the importance of a timely diagnosis Georgios Karpathakis, Sweden
- **14:25** Snapshot: screening, diagnosis and treatment of ADHD in adults Larry Klassen, Canada
- 14:40 Closing comments
 David Bull, UK

EXHIBITION FLOOR PLAN





LIST OF EXHIBITORS

Name	Booth No
Accord Healthcare (Polska)	6
Adamed Pharma S.A.	21
Angelini SPA	7
Apotex	30
Biofarm	23
Brain Plan for Poland	16
BrainsWay	12
CINP - The International College of Neuropsychopharmacology	1C
Deymed Diagnostic	1b
Elsevier	1 - Shared
EUFAMI - European Federation of Associations of Families of People with Mental Illness EFPT)	29
European Brain Council (EBC)	26
European College of Neuropsychopharmacology (ECNP)	28
European Federation of Psychiatric Trainees	16c
European Psychiatric Association (EPA)	1 - Shared
French Congress of Psychiatry	27
GAMIAN-Europe	26a
Gedeon Richter Plc	10 - Shared
Genomind	14
H. Lundbeck A/S	2
Janssen Pharmaceutica NV	9
MagVenture	19
Medicarrera	1a
Neuraxpharm Holdco SARL	15
Neurim Pharmaceuticals	13
Neurosoft	24
Paragona & Sahlgrenska University Hospital	1d
Polskie Towarzystwo Psychiatryczne	16a
RECORDATI S.p.A	10 - Shared
Sage Therapeutics GmbH	11
Sooma Medical	22
Soterix Medical, Inc.	25
Takeda	3
VP Valeant Sp. z o.o. sp. j.	21a
Wisepress LTD	6a
World Psychriatric Association	16b
3rd WADD World Congress and 6th edition of SEPD International Congress	31

COMPANY PROFILES

Accord Healthcare (Polska)

Taśmowa 7 Warszawa 02-677 Poland Booth #: 06



https://www.accord-healthcare.com/

Accord Healthcare is a young and dynamic pharmaceutical company, involved in the development, manufacturing and distribution of pharmaceutical products to over 70 markets around the world.

Adamed Pharma S.A.

Pieńków, ul. M. Adamkiewicza 6A Czosnów 05-152 Poland Booth #: 21



https://adamed.com.pl/

Adamed is a Polish pharmaceutical and biotechnology company manufacturing more than 580 products offered to the patients in 65 countries around the world. The company employs over 2000 people. The company's intellectual property is protected by more than 190 patents all over the world. Moreover, Adamed holds the controlling interest of one of the fastest growing Vietnam's pharmaceutical companies – Dat Vi Phu. It has been the biggest direct private Polish investment in Vietnam.

Angelini SPA

Viale Amelia Roma 70 00181 Italy Booth #: 07



https://www.angelini.it/

Angelini Pharma is an international company with branches in 18 countries and worldwide product distribution. The area of CNS-acting drugs is the field where Angelini has achieved the greatest successes and recognition at world level as a result of the discovery and development of trazodone for the treatment of mood disorders. Trazodone is currently marketed in more than 50 countries worldwide. Angelini continues to reinforce the position in Mental Health with the enlargement of the product portfolio with the recent launch of lurasidone in the treatment of schizophrenia, loxapine in mild-to moderate agitation and the licensing-in of lithium sulfate in bipolar disorders. The RR&D is steadily searching and developing new solutions in the area of CNS, in particular in highly disabling pathologies of the nervous system and with great attention to the paediatric population.



Apotex

Ostrobramska, 95

Warsov 04-118 Poland

Booth #: 30

http://www.apotex.com/pl/pl/default.asp

Pharmaceutical Company

APOTEX

30 lat dbamy o zdrowie pacjentów

Biofarm

Walbrzyska 13 Poznan 60-198 Poland Booth #: 23

http://www.biofarm.pl

Biofarm Sp. z o.o. in Poznań is one of the largest manufacturers of pharmaceuticals in Poland. We have been enjoying a dynamic growth since 1988 when the company was officially launched. Biofarm's consistent growth of its market position is due to the high quality of its products and the continuous efforts to expand its product portfolio. In 2001 and as one of the first pharmaceutical companies on the Polish market, Biofarm was granted the GMP certificate that confirms meeting the highest standards of pharmaceutical manufacture quality.

Brain Plan for Poland

Gorczewska 228/131

Warsaw 01-460 Poland

Booth #:16

http://www.swiatmozgu.pl/

"Brain Plan for Poland" is the strategy document developed by wide multi stakeholder public –private partnership, which main aim is to improve quality of life people with brain diseases. Our top priorities are - To increase social awareness and develop prevention programs - To shorten the diagnostic delay and to start treatment as early as possible - To implement multidisciplinary approach and to implement coordinated care - To develop and disseminate evidence based recommendations and socially responsible policy. Main partners od projects are: NeuroPositive Foundation(leader), Łazarsi University, DZP Law Firm, European Brain Council, Polish Brain Council



BrainsWay

19 Hartum St. Jerusalem 9777518 Israel Booth #: 12



http://brainsway.com

BrainsWay is engaged in the research, development and marketing of BrainsWay-Therapy, a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a proprietary and breakthrough technology called Deep-TMS, which can reach deeply and broadly into the brain and produce nerve stimulation or suppression. BrainsWay is currently FDA cleared for the treatment of Major-Depressive-Disorder, and has reimbursement by insurers, including both commercial and government payers, covering about 90% of the US population. The Company's systems are sold worldwide as well, with CE mark for a variety of indications including Major-Depressive-Disorder, Obsessive-Compulsive-Disorder, Smoking-Cessation, Chronic-Pain, Post-Traumatic-Stress-Disorder and more.

CINP - The International College of Neuropsychopharmacology (CINP)



Nussdorfer Strasse 20/22 Vienna 1090 Austria Booth #: 1c https://cinp.org/

The International College of Neuropsychopharmacology (CINP) is a truly worldwide organization established over 60 years ago in Zurich, Switzerland and can count on widespread support from all over the world by its active members. Holding regular meetings in form of Training, Educational Programs, International Meetings, and World Congresses, CINP reaches interested researchers all over the world. Clinicians hear about the latest research advances and new treatments whilst researchers hear about new clinical needs and problems. Therefore, CINP is dedicated to promoting research and education on a worldwide basis.



Deymed Diagnostic

Velký Dřevíč 91 Hronov 549 32 Czech Republic Booth #: 1b https://deymed.com/



The company was founded in 1997 and its first product was developing a 32 channel EEG device which was completed and sold in 1998. In the following years additional neurology products have been developed including EMG, PSG and TMS devices. The initial sales were to the Czech Republic but soon thereafter were offered in international markets. Due to the high level of innovation and modern design of the products, Deymed has become an established worldwide leader in neurology for both clinical and research applications.

Elsevier

Radarweg 29 Amsterdam 1043 NX The Netherlands

Booth #: 1-Shared Booth https://www.elsevier.com





EUFAMI - European Federation of Associations of Families of People with Mental Illness

Diestsevest 100 Leuven 3000 Belgium Booth #: 29 http://eufami.org/



EUFAMI is an international NGO based in Belgium committed to improving the care for and welfare of people with mental ill health. Our mission is to represent at the European level all family members of persons that are affected by mental ill health and to protect their rights and interests. We would like to see family carers acknowledged on an equal footing with professional staff and mental health care services in the community should be adequate to enable family members of people with mental ill health to choose whether to become informal caregivers. EUFAMI has a number of programmes that support people that are affected by severe mental ill health and the organisations representing them across Europe.

European Brain Council (EBC)

Rue d'Egmont 11 Brussels 1000 Belgium Booth #: 26



https://www.braincouncil.eu

The European Brain Council (EBC) is a network of key players in the "Brain Area", with a membership encompassing scientific societies, patient organisations, professional societies and industry partners. A non-profit organisation based in Brussels, its main mission is to promote brain research with the ultimate goal of improving the lives of the estimated 179 million Europeans living with brain conditions, mental and neurological alike. With the aim to speak with one voice, EBC stands as the platform to foster cooperation between its member organisations and other stakeholders, consistently promoting dialogue between scientists, industry and society. As showcased by its growing portfolio of projects, research and policy papers, as well as events, EBC emphasizes the importance of continued interaction with the European Institutions to build strong European health policies, raising awareness

European College of Neuropsychopharmacology (ECNP)



Bolognalaan 28 Utrecht 3584CJ The Netherlands Booth #: 28 https://2019.ecnp.eu/

ECNP is Europe's leading independent forum for the science of CNS treatments. The ECNP Congress showcases the world's best disease-oriented brain research, annually attracting between 4,000 and 6,000 neuroscientists, psychiatrists, neurologists and psychologists. ECNP's wide range of scientific and educational activities, programmes and events make it the largest non-institutional supporter of applied and translational neuroscience research and education in Europe.

European Federation of Psychiatric Trainees (EFPT)

20 Avenue de la Couronne Brussels 1050 Belgium Booth #: 16c http://www.efpt.eu



The European Federation of Psychiatric Trainees (EFPT) is an umbrella organisation for National Trainee Associations (NTA) of postgraduate doctors training in psychiatry within the WHO Europe Region. The EFPT currently has 38 member organisations in 36 countries and represents many thousands of trainees. The EFPT works on a range of projects, including running a popular exchange programme, supporting the establishment of NTAs and conducting trainee-led international research.



European Psychiatric Association (EPA)

15, avenue de la liberté Strasbourg 67000 France

Booth #: 1 Shared Booth http://www.europsy.net

With active individual members in as many as 88 countries and 40 National Society/ Association Members who represent more than 78,000 European psychiatrists, the European Psychiatric Association is the main association representing psychiatry in Europe. EPA's activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. EPA deals with psychiatry and its related disciplines, and focuses on the improvement of care for the mentally ill as well as on the development of professional excellence.

French Congress of Psychiatry

CH Sainte Anne, CMME Paris 75014 France Booth #: 27

http://www.congresfrancaispsychiatrie.org

The French Congress of Psychiatry was born on 2 December 2009 in Nice. This year we will celebrate its 10th anniversary.

GAMIAN-Europe

60 rue du Trone Brussels 1050 Belgium Booth #: 26a

https://www.gamian.eu/

Global Alliance for Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) is a patient-driven pan-European organisation, representing the interests of persons affected by mental illness and advocates for their rights. Our main objectives are: advocacy, information and education, anti-stigma and discrimination, patients' rights, co-operation, partnerships and capacity building. GAMIAN-Europe was established in 1998 as a representative coalition of patient organisations. Putting the patient at the centre of all issues of the EU healthcare debate, the organisation aims to bring together and support the development and policy influencing capacity of local,

regional and national organisations active in the field of mental health.







Gedeon Richter Plc

Gyömrői str. 19-21 Budapest 1103 Hungary Booth #: 10



http://www.richter.hu/en-US/Pages/default.aspx

Headquartered in Hungary, Gedeon Richter is an innovation-driven specialty pharmaceutical company. It has manufacturing subsidiaries in five countries and markets its products in one hundred countries. With a 1000-strong R&D team the company boasts the biggest pharmaceutical research centre in CEU. CNS drugs are important parts of its portfolio and constitute the focus of its original research. The company's latest achievement is the original atypical antipsychotic compound, cariprazine, already marketed in the US for the treatment of bipolar mania and schizophrenia since March 2016. In 2017 it received marketing authorization in the EU for the treatment of schizophrenia in adult patients and has been marketed in the majority of the European Union.

Genomind

2200 Renaissance Blvd, Suite 100 King of Prussia 19406 USA Booth #: 14 GEN MIND

http://www.genomind.com

Genomind is a unique personalized medicine platform that brings innovation to healthcare around the world. Genomind, comprised of pioneering scientists and thought leaders in brain health and genetics, delivers actionable insights to clinicians, healthcare partners and individuals in order to improve the quality of human life. Genomind is a CLIA certified and CAP accredited laboratory. Learn more at www.genomind.com.

H. Lundbeck A/S

Ottiliavej 9 Valby 2500 Denmark Booth #: 2 http://www.lundbeck.com



Lundbeck – improved treatment and a better life for people living with psychiatric and neurological disorders. A global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research in neuroscience with focus on depression, schizophrenia, Parkinson's disease and Alzheimer's disease, www.lundbeck.com



Janssen Pharmaceutica NV

Turnhoutsweg 30, B-2340 Belaium B-2340 Bermuda Booth #: 9

https://www.janssen.com

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

MagVenture

Lucernemarken 15 Farum 3520 Denmark

Booth #: 19

https://www.magventure.com/

MagVenture TMS Therapy is a complete system for the treatment of depression. It is simple, effective and easy to use for any psychiatrist wishing to give patients an alternative to antidepressants. High quality, consistency, patient comfort, and patient management, are key elements in the system which was the first to be CE-marked for treating Major Depression Disorder in adults. The MagVenture TMS Therapy system was FDA cleared in 2015 and NICE has also issued full guidance on TMS for depression. All products are sold through subsidiaries in Germany, the UK, and the USA, as well as an extensive distributor network.

Medicarrera

Passeig de Gracia 6, 2º 2ª Barcelona 08007 Spain Booth #: 1a

http://medicarrera.com/

MediCarrera is an authorized partner of the public health care in Sweden, Norway and Denmark. On behalf of public hospitals, primary care centers and dental clinics we select candidates, organize the intensive language program for the doctors and their families and the relocation to the new country. With the MediCarrera program every family member will speak the language starting with the first day in the new country. Since 2003 we have been helping doctors, nurses and dentists take their careers to the next level working in the Swedish, Norwegian or Danish healthcare system. All the services of MediCarrera are free of charge for the candidates.



Janssen 7 Cohmon-Gohmon



MediCarrera



Neuraxpharm Holdco SARL

1-3 Boulevard de la Foire Luxembourg L-1528 Luxembourg Booth #: 15

https://www.neuraxpharm.com

European Leader in pharmaceutical products for the Central Nervous System.

Neurim Pharmaceuticals

27 HaBarzel st. Tel Aviv 6971039 Israel

Booth #: 13 http://www.neurim.com

Neurim Pharmaceuticals Ltd. (www.neurim.com) is a neuroscience pharma company, focusing on discovering and developing innovative drugs for central nervous system diseases. Neurim has a strong and innovative product pipeline, intended for insomnia, Alzheimer's disease, and pain. Its first approved drug, Circadin®, is available in more than 45 countries around the world. In response to the unmet medical need in the field of pediatric insomnia among children with ASD, Neurim developed Slenyto® - an innovative age-appropriate formulation, indicated for the treatment of insomnia in children and adolescents aged 2-18 with ASD or Smith-Magenis syndrome (SMS).

Neurosoft

5, Voronin str. Ivanovo 153032 Russia Booth #: 24



Neurosoft is the only company on the market developing and producing both professional EMG and NCS systems and TMS systems. This brings the machine at unique mode of integration between TMS and EMG. Such tests as SICI, IHI, TST, etc can be done routinely without any integration or adjustment work. You just need to select test template from the list. Therapeutic version of device goes with Windowsbased software Neuro-MS.NET. It is a treatment planner and patients' database in one package. The software includes wide list of templates for most diseases cured with TMS: depression, tinnitus, stroke, Parkinson's disease, etc.









Paragona & Sahlgrenska University Hospital

paragona



Al. Jana Pawła II 29 Warsaw 00-867 Poland Booth #: 1d


https://www.paragona.com

Paragona has helped over 1000 medical professionals to start a new life abroad. With us you have the opportunity to take your career to Sweden and Sahlgrenska University Hospital, Gothenburg - a hospital working with highly specialized care, research and innovation with great opportunities for personal and professional development. After finding you an appropriate position, we will walk you through all of the paperwork and organize free language training. Working in hospitals recommended by us ensure competitive wages, favorable social conditions and will also give you time for your family as well as for developing your hobbies and interests.

Polskie Towarzystwo Psychiatryczne

Sobieskiego 9 Warszawa 02-957 Poland Booth #: 16a





RECORDATI S.p.A

Via M. Civitali 1 milano 20148 Italy Booth #: 10



Recordati is a European specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added products in cardiovascular, urological, psychiatric and rare diseases areas.





Sage Therapeutics GmbH

Dammstrasse 19 Zua 6301 Switzerland Booth #: 11

https://www.sagerx.com/

Sage Therapeutics is committed to discovering and developing life-altering therapies to treat central nervous system (CNS) disorders, and we are dedicated in our pursuit to deliver new medicines with the goal of making life better for patients and their

Servier

families.

35 rue de verdun Suresnes Cedex 92284 France

https://servier.com/

Servier is an international independent pharmaceutical company governed by a nonprofit foundation. Neuropsychiatry is one of the fifth therapeutic areas where research and development of innovative therapeutic solutions for patients are concentrated. Agomelatine was approved in 2009 for the treatment of major depressive episodes in adult. Deprexis® is an effective, individualized and convenient online treatment for depression based on CBT. Post-stroke functional recovery and autism spectrum. disorders are also areas of interest for Servier, www.servier.com

Sooma Medical

Kuortaneenkatu 2 Helsinki 00510 Finland Booth #: 22

https://soomamedical.com

Sooma is a Finnish medical device company developing world class non-invasive brain stimulation devices for home based treatment of both neurological and psychiatric disorders. Since its establishment in 2013, Sooma has been working closely with leading experts in psychiatry and clinical neurophysiology to provide the best possible care for patients around the world. Sooma tDCS, a low threshold therapy solution for major depressive disorder and chronic pain is a safe, effective and suitable treatment option for most people. All Sooma products are CE-marked as medical devices, which ensures that the products are safe to use in patient work and also effective within their indication of use.









Soterix Medical, Inc.

237 West 35th Street, 1401 NEW YORK 10001 USA

Booth #: 25

https://soterixmedical.com/



Soterix Medical is the world leader in non-invasive neuromodulation and brain stimulation technology. Leveraging the most advanced scientific understanding, Soterix Medical technology is the forefront of neuromodulation therapy and trials for the treatment of neuropsychiatric disorders. Soterix Medical tDCS-LTE treatment is approved in the European Union for the treatment of Major Depression in adult patients. The tDCS-LTE system is a battery powered medical device that stimulates the brain via electrodes on the scalp. It is a highly promising therapy for Major Depression without the systemic side effects commonly associated with oral antidepressant medications.

Takeda

Takeda Global Headquarters 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan Booth #: 3 https://www.takeda.com/



Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished 237-year history in Japan. We are thrilled to be given a greater opportunity to make a significant difference in even more people's lives.

VP Valeant SP. z o. o. sp. j. / Bausch Health

BAUSCH Health

wisepress.com

Przemysłowa 2 Rzeszów 33-595 Poland Booth #: 21a

https://www.bauschhealth.com/

VP Valeant is part of the international pharmaceutical group Bausch Health Companies Inc. responsible for the provision of advertising and marketing services for medicines to improve the health of patients around the world. It belongs to the group of 10 largest pharmaceutical companies in Poland. The Company's portfolio includes over 360 brands, of which over 200 both prescription and non-prescription drugs are actively promoted. Thanks to the diversified product portfolio, the company operates in various therapeutic areas - cardiology, ophthalmology, urology, gastroenterology, oncology, dermatology, neurology and psychiatry. VP Valeant is committed to improving the health and lives of patients, therefore, as part of its social mission and in the spirit of accepted values, it provides financial and material support to healthcare entities and to non-governmental organizations.

Wisepress LTD

15 Lvon Road London SW19 2RL IJК

Booth #: 6a

http://www.wisepress.com Wisepress.com, Europe's leading conference bookseller, has a complete range of

books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you - Wisepress will

deliver worldwide. In addition to attending 200 conferences per year, Wisepress has

a comprehensive medical and scientific bookshop online with great offers.



World Psychiatric Association (WPA)

Psychiatric Hospital 2, ch. du Petit-Bel-Air Geneva 1225 Chêne-Boura. Switzerland Booth #: 16b



http://wcp-congress.com

The WPA is an association of national psychiatric societies aimed to increase knowledge and skills necessary for work in the field of mental health and the care for the mentally ill. Its member societies are presently 140, spanning 120 different countries and representing more than 200,000 psychiatrists. The WPA organizes the World Congress of Psychiatry every three years. It also organizes international and regional congresses and meetings, and thematic conferences. It has 72 scientific sections, aimed to disseminate information and promote collaborative work in specific domains of psychiatry. It has produced several educational programmes and series of books. It has developed ethical guidelines for psychiatric practice, including the Madrid Declaration (1996). Visit the WPA association Website: http://www. wpanet.org/

3rd WADD World Congress and 6th edition of SEPD International Congress

CALLE ERASO 36, 2º PLANTA MADRID 28028 Spain Booth #: 31



https://icdd-congress.com/

This International Congress, specialized on Dual Disorders, will take place in Madrid from June 19th to June 22nd 2019, both dates included. WADD, in conjunction with the Spanish Society on Dual Disorders-SEPD, convene you to this major event, to discuss on Dual Disorders, psychiatry and addictions, on the theme: "Precision Psychiatry in Dual Disorders" This event provides an excellent opportunity to share academic developments, research findings and clinical practice experiences, with delegates from around 70 countries. This edition will introduce a new Congress model, with an innovative program based on a central track on Neurosciences, in which international opinion leaders on psychiatry will be present, having single issue/ monothematic tracks, focused on several aspects in Dual Disorders.

NOTES	



NOTES	



Sage is committed to developing novel medicines for CNS disorders, including postpartum depression.

Visit us at www.sagerx.com





A symposium sponsored by Angelini at the EPA 2019 - 27th European Congress of Psychiatry

The Burden of Schizophrenia across age and gender

Sunday, April 7th 2019 - 13:15-14:45 Warsaw Expo XXI Congress Venue - Hall E

Rationale

The aim of the symposium is to present and discuss data on the differences across age and gender groups in schizophrenia. The talks will address the aspects of disease onset and evolution, symptoms, treatment response and tolerability and finally the differences across the subgroups from a pharmacoeconomic perspective.

Programme

Chairman: Sofia Brissos - Lisbon, Portugal

Gender differences in schizophrenia symptoms

Anita Riecher-Rössler - Basel, Deutschland

Pharmacological treatment selection: age and gender differences David Taylor - London, U.K.

The economic burden of schizophrenia across gender and age groups Andrea Fagiolini - *Siena, Italy*

Can we still improve patient functioning in schizophrenia?



Chair: ISTVÁN BITTER (Hungary)

Improving negative symptoms and patient functioning – state of the art STEFAN LEUCHT (Germany)

Mechanism of action of cariprazine: molecular and behavioral effects related to negative symptoms

GIORGIO RACAGNI (Italy)

Clinical studies and real life experience: challenges and cases
PETER FALKAI (Germany)





EPA 2019 Warsaw, Poland April 6-9, 2019

Sunday, April 7, 2019 12:30-13:10

Theater in the exhibition hall

Training session on deprexis®, an online CBT program

Speaker:

B. Meyer (GAIA AG, Germany)

Interactive session with the audience

Monday, April 8, 2019 12:30-13:10

Theater in the exhibition hall

Feedback on deprexis® from clinical practice experience

Speakers:

T. Kanellopoulos (Greece)

R. Psaras (Greece)

Interactive session with the audience



This symposium is initiated, organised and funded by Takeda

Takeda Satellite Symposium

EPA 2019, 27th European Congress of Psychiatry Expo XXI Convention Center, Warsaw, Poland

Monday 8th April 2019: 13:15-14:45. HALL B.

PLEASE JOIN US!

Missed or misdiagnoses: could it be ADHD?

Scientific Programme

13:15-13:20 Chairman's welcome David Bull 13:20-13:35 Scene-set: ADHD in general adult psychiatry Susan Young 13:35-14:05 ADHD and comorbidities: differential diagnosis: Depression and Anxiety Larry Klassen Bipolar Disorder Peter Mason Borderline Personality Disorder Alexandra Philipsen Substance Use Disorder Antoni Ramos Panel discussion forum 14:05-14:25 **Voice of the patient:** the importance of a timely diagnosis Georgios Karpathakis 14:25-14:40 Snapshot: screening, diagnosis and treatment of ADHD in adults Larry Klassen

Speakers

Georgio Karpathakis, Patient and Campaigner, Underbara ADHD, Stockholm, Sweden Larry Klassen, Consultant Psychiatrist, Eden Mental Health Centre, Manitoba, Canada Peter Mason, Consultant Psychiatrist, The Stein Centre, St Catherine's Hospital, Liverpool, UK Alexandra Philipsen, Professor of Psychiatry and Psychotherapy, University of Bonn, Germany Antoni Ramos, Professor of Psychiatry, Vall d'Hebron University Hospital, Barcelona, Spain Susan Young, Forensic and Clinical Psychologist, Private Practice, London, UK



David Bull

14:40-14:45 **Closing comments**